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CHAPTER	1:	Introduction	
	 	 1	 	 	
In order for cells to survive, they must coordinate complicated cellular signaling 
responses to many different types of stimuli including DNA damage. Preserving genomic 
integrity is key to maintaining normal cellular functions along with preventing the 
accumulation of mutations that can lead to cell death, disease, or aberrant cell growth. 
Although the pathways involved in repairing various DNA lesions have been studied for 
years, there remain fundamental gaps in understanding the overlap of these pathways and 
the machinery involved in certain cases. This dissertation characterizes a previously 
unknown component of a Fanconi anemia-independent interstrand crosslink (ICL) DNA 
repair pathway and explores its importance in protecting cells against ICL damage.  
1.1 DNA Damage Response 
     Every day, cells encounter many different types of DNA damage that if left unrepaired 
can result in cell death or diseases such as cancer. Detection and repair of DNA lesions is 
tightly regulated and DNA damage checkpoint pathways are interconnected1. DNA 
damage checkpoints are signaling cascades that delay cell cycle progression to allow for 
repair of DNA lesions2. Eukaryotic cells have four main checkpoints throughout the cell 
cycle including the G1/S checkpoint, the intra-S phase checkpoint, the G2/M checkpoint 
and the S/M checkpoint3. In addition to arresting cell cycle progression, DNA damage 
checkpoint factors initiate DNA damage response repair pathways, delivery of repair 
proteins to sites of damage, and activation of transcriptional responses4. There are several 
key components of DNA damage checkpoints including sensors, mediators, transducers,  
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Figure from Marechal, et al. 2013 (3). 
 
Figure 1. DNA Damage Response signaling pathway components. Like other signal 
transduction pathways, the DDR signaling pathway consists of signal sensors, 
transducers, and effectors. The sensors of this pathway are proteins that recognize DNA 
structures induced by DNA damage and DNA replication stress. The transducers of this 
pathway are kinases, including ATM, ATR, and their downstream kinases. The effectors 
of this pathway are substrates of ATM, ATR, and their downstream kinases. These 
effectors of ATM and ATR are involved in a broad spectrum of cellular processes that 
are important for maintenance of genomic stability of organisms. 
. 
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and effectors5 (Figure 1). Sensor proteins are required to detect DNA lesions and initiate 
DNA damage checkpoint activation6. Meditator proteins interact with transducer proteins 
as an additional layer of specificity to activate the proper downstream protein factors 
depending on the phase of the cell cycle6. Kinases transduce the checkpoint activation 
signal by phosphorylating additional protein factors, called effectors, that act to regulate 
other cellular processes7. Proteins can have more than one role in DNA damage 
checkpoint activation allowing for multiple levels of regulation and complexity in DNA 
damage checkpoint activation and signal propagation5. If DNA damage is too extensive, 
and cannot be repaired, the cell will initiate apoptosis, or programmed cell death7.  
 
     DNA damage can result from exogenous sources including ultraviolet radiation or 
chemotherapeutics and can also result from endogenous sources including, but not 
limited to, reactive aldehydes8–10. Each lesion is repaired by a specific pathway that must 
act to detect the lesion, excise the lesion, and repair the DNA (Figure 2). In the absence 
of DNA repair, cells accumulate damage resulting in inhibition of basic cellular 
processes, including replication and transcription, or the formation of chromosomal 
aberrations11 (Figure 2). The main DNA repair pathways include: mismatch repair 
(MMR), base-excision repair (BER), nucleotide excision repair (NER), non-homologous 
end joining (NHEJ), homologous recombination (HR), and interstrand crosslink (ICL) 
repair4. However, there are still gaps in our understanding of which proteins are involved 
in each step of repair and how the various DNA damage response pathways are 
interconnected. Interestingly, there is significant overlap in the protein machinery 
responsible for detecting, excising, and repairing different DNA lesions4 as well as in the 
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Figure 2. DNA damage response overview and Interstrand Crosslink Repair. Cells 
encounter many different types of endogenous and exogenous DNA damaging agents and 
require an extensive network of proteins to detect the lesion, remove the damage, and 
repair the DNA to prevent inhibition of basic cellular processes such as transcription and 
replication. The inability to repair DNA lesions results in persistent damage that can 
cause aging and various diseases such a cancer. Interstrand crosslinks require the 
coordination of the Fanconi anemia pathway, nucleotide excision repair, translesion 
synthesis, and homologous recombination and are thus complicated lesions to repair. 
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contribution of various protein components to each DNA repair pathway. For example, 
MMR and HR are linked during replication where MMR replaces mismatched bases and 
HR provides replication fork stability12. The coordination of these two distinct DNA 
repair pathways is required for maintaining genomic stability and preventing the 
accumulation of DNA damage. The importance of DDR crosstalk is also exemplified in 
ICL repair where the repair of crosslinks requires a unique combination of nucleotide 
excision repair, translesion synthesis, and homologous recombination13. Thus, the 
identification and characterization of additional protein components of the DNA damage 
response is crucial in developing a deeper understanding of how cells handle genomic 
stress.  
1.2 Mismatch Repair 
The mismatch repair pathway is responsible for detecting, removing, and repairing 
insertions and deletions (IDLs) that result from microsatellite regions in the genome 
along with repairing base-base mismatches14. Microsatellite regions are regions of short 
repetitive sequences that can be unstable during DNA replication resulting in the DNA 
replication primer dissociating and re-annealing at a different location in the 
microsatellite region14. Microsatellite instability (MSI) refers to the hypermutability of 
these regions including the possibility of insertions and deletions that can lead to 
accumulated mutations and cancer15. In addition to preventing MSI, the MMR pathway 
also replaces base-base mismatches that are not detected or repaired by the proofreading 
activity of the DNA polymerase, a critical component for maintaining genetic integrity 
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during DNA replication14. Combined, MMR is responsible for increasing genomic 
fidelity by orders of magnitude16. An important step in MMR is the cleavage of the 
heteroduplex structures resulting from IDLs or base-base mismatches and resection of the 
region by 3’-5’ or 5’-3’ exonucleases12. Exonuclease 1 (EXO1), a 5’-3’ exonuclease from 
the FEN1 family of structure specific nucleases, has been implicated in this process in in 
vitro and in vivo studies and is, surprisingly, the only required exonuclease for MMR in a 
reconstituted system17. In addition to functioning in MMR, EXO1 has exonuclease 
activity on dsDNA and also flap endonuclease activity18 and, as described below, is 
involved in repair of double-stranded DNA breaks (DSBs).  
1.3 Base Excision Repair 
In addition to being able to repair base-base mismatches, cells also need to be able to 
replace bases that have been damaged by endogenous damaging agents such as reactive 
oxygen species or by exogenous damaging agents such as ultraviolet light. These changes 
result in chemical instability and structural alterations to the DNA19.  If oxidized, 
alkylated, or deaminated bases are left unrepaired by the BER pathway, the cell can 
accumulate damage resulting in DNA breaks during replication20. BER removes these 
lesions by using a toolkit of DNA glycosylases to generate apurinic (AP) sites, followed 
by additional processing of the AP site by AP endonuclease 1 (APE1), and replacement 
of the damaged nucleotide with a new nucleotide21. There are several factors that 
contribute to the selection of short-patch BER or long-patch BER, including cell cycle 
stage and the type of damage present on the DNA22. Short-patch BER replaces only the 
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damaged nucleotide while long-patch BER replaces a small region of nucleotides 
surrounding the damage site22. In long-patch BER, flap endonuclease 1 (FEN1) is 
responsible for cleaving the 5’ flap that forms as a result of DNA polymerase ß/Ø/∑ 
polymerizing 2-15 nucleotides to replace the damaged base resulting in the damaged 
region being displaced on the flap23. FEN1 is a member of a structure-specific family of 
nucleases that act in DNA replication and repair. In addition to long-patch BER, FEN1 
also functions in processing Okazaki fragments during DNA replication24.  
1.4 Nucleotide Excision Repair 
     Another DNA repair pathway that functions to remove damaged DNA is nucleotide 
excision repair (NER), which removes DNA damaged by ultraviolet (UV) light, various 
environmental damaging agents, bulky lesions, and some chemotherapeutics25. 
Importantly, this pathway is also required during the processing of interstrand crosslinks, 
as is discussed below.   
  Nucleotide excision repair has two main repair mechanisms: global genome NER (GG-
NER) and transcription-coupled NER (TC-NER). GG-NER is responsible for scanning 
the genome for helical distortions caused by any of the previously listed DNA mutagens. 
TC-NER, by comparison, functions with transcription machinery to remove DNA lesions 
on genes that are transcribed for normal cellular function26. The set of enzymes that 
function in repair must be able to recognize many different lesions that represent NER 
substrates including cyclopurines generated by reactive oxygen species (ROS), 
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cyclobutane-pyrimidine dimers (CPDs), 6-4 pyrimidine-pyrimidone photoproducts (6-
4PPs) from UV radiation, and additional bulky adducts from various sources25. The 
ability to recognize a wide range of lesions is the result of the NER system developing 
the ability to group together bulky lesions based on their structural commonalities27. 
Although the sub-pathways utilize the same core NER machinery to remove and repair 
the lesions, there are different initiation events for the two processes and the factors 
involved in the initiation event must be highly sensitive to recognizing NER-specific 
damage. GG-NER is initiated by complexes of factors XPC and XPE while TC-NER is 
initiated when RNA pol II is inhibited by damage encountered during transcription28.  
     The steps of NER can be described as initiation or damage recognition, assembly of 
the multi-subunit repair complex, excision of the damaged DNA, and DNA repair 
synthesis followed by strand ligation29. In the case of GG-NER, initiation results from 
XPC coming in contact with damaged DNA as it scans the genome, an event that signals 
for assembly of the repair complex. In TC-NER, initiation results from collision of RNA 
polymerase II with damaged DNA causing a block in transcription30. After TFIIH 
complex assembly, including binding of factors XPA, RPA, and XPG, TFIIH opens the 
helix to allow the endonucleases XPF/ERCC1 and XPG to access and excise the 
damaged DNA31. DNA synthesis and ligation is then completed by replication proteins 
DNA polymerase σ/ε, PCNA and Lig132. The ability to repair lesions that block the 
transcription complex in a timely manner is critical to maintaining normal gene 
expression and protein levels in the cell, making TC-NER a particularly important repair 
process. People who inherit NER protein deficiencies (XPA-XPG) display the UV 
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intolerance disease Xeroderma Pigementosum (XP)33. XP is characterized by an extreme 
sensitivity to sunlight with any exposure resulting in severe blistering and burns along 
with progressive mental decline, cancer and eventual death34. Although XP is not the 
only NER-associated disease, XP is a chronic disease with no known treatments that 
leaves patients with a terrible quality of life.  
1.5 Double Strand Break Repair 
The two main DNA repair pathways that detect and repair double-strand breaks 
(DSBs) are homologous recombination (HR) and non-homologous end joining (NHEJ). 
Although both pathways function to repair DSB lesions, they act at different points in the 
cell cycle, and are regulated by different effector enzymes. End-resection, and thus HR 
only, drives the commitment step of end-resection35. DSBs can form as a result of DNA 
damaging agents such as IR or as a result of genomic stress such as the persistent stalling 
of a replication fork36. DSBs are highly cytotoxic and when left unrepaired can result in 
insertions and deletions in the DNA, chromosomal aberrations, and cell death37.  
Homologous recombination is a high-fidelity repair process that functions in the S and 
G2 phases of the cell cycle to repair DSBs, rescue stalled replication forks, and reinitiate 
collapsed replication forks38. It is also essential to the processing of interstrand cross-
links (ICLs), described in the next section.  HR relies on the sister chromatid of the 
damaged DNA to serve as a template for repair39. The lesion is typically detected by the 
Ataxia telangiectasia mutated (ATM) sensor kinase resulting in the phosphorylation of 
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histone variant H2AX to generate the damage signal γH2AX40. This signaling event 
recruits the MRN complex consisting of MRE11, RAB50, and NBS1 along with BRCA1 
which initiate processing of the end of the DNA of the DSB41. Although MRN is 
responsible for initial processing of the DSB, other nucleases are required to generate the 
3’ single-stranded DNA overhang created by resecting the 5’ strand. CtIP is an important 
nuclease required for end-resection and in certain cases where more extensive end-
resection is required other nucleases may be involved including EXO1 and Dna242,43. As 
stated previously, 5’-3’ end resection of the DSB is the determinant step of whether the 
HR or NHEJ pathway acts to repair the damage and thus is highly regulated44. There are 
also helicases including BLM and WRN that act to stimulate nuclease activity to expedite 
repair45.  
After generation of the 3’ ssDNA overhang, the single-stranded DNA binding protein 
replication protein A (RPA) binds the ssDNA overhang while recruiting the HR protein 
RAD5143. RPA acts to protect ssDNA from additional degradation or damage by other 
damaging sources or additional nuclease processing46. Aided by a mediator protein, 
RAD51 then displaces RPA and initiates strand invasion and formation of a D-loop, in 
which the protein/DNA complex invades the homologous chromosome searching for a 
region of homology to the ssDNA overhang47. After identification of the homologous 
region, a DNA polymerase is able to synthesize new DNA at the location of the DSB. 
The resulting repair intermediate can be resolved by synthesis-dependent strand 
annealing or by the action of resolvase enzymes (required for repair of a Holliday 
Junction)48. GEN1 is a resolvase enzyme that is a member of the FEN1 family of 
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nucleases and acts to resolve Holliday Junctions49. Holliday Junctions are four-stranded 
DNA structures that require two cleavage events to process the Holliday Junctions to 
downstream repair steps48. 
Although HR is the preferred method of repairing DSBs, due to HR being an 
extremely high fidelity process, there are three other more error-prone pathways by 
which cells can repair DSBs including classical non-homologous end-joining (C-NHEJ), 
alternative end-joining (Alt-EJ), and single-strand annealing (SSA)44. Cell cycle is a 
major determinant of which pathway is chosen, as SSA and Alt-EJ both require activation 
of end resection nucleases MRN and CtIP to repair the DSB and these nucleases are only 
active during S and G2 phases50. C-NHEJ on the other hand, does not require any end 
resection and thus functions in G1 and M phases of the cell cycle11. C-NHEJ is the main 
pathway for repairing DSBs in adult mammalian cells and is initiated when a DSB is 
recognized by the Ku80/Ku70 DNA binding proteins51. This binding event recruits DNA-
PKs and activates the catalytic component of the complex52. In certain cases other 
proteins are involved including Artemis and DNA ligase IV53. Although C-NHEJ is a 
relatively quick process, it is fundamentally error-prone in that the blunt ligation of the 
ends of the DSB can result in insertions and deletions53. Alt-EJ/SSA is a mutagenic repair 
pathway that utilizes a mix of end resection and homology-based repair, therefore 
competing with RAD51 and HR50. Even though NHEJ pathways are error-prone, they are 
vitally important outside of S and G2 phases of the cell cycle and when cells are HR 
deficient54.  
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1.6 Interstrand Crosslink Repair 
Interstrand crosslinks (ICLs) are a highly cytotoxic form of DNA damage that, when 
left unrepaired, result in the inhibition of cellular processes including transcription and 
replication13. ICLs are repaired by interstrand crosslink repair which is a complex repair 
pathway involving the coordination of several previously discussed DDR pathways 
including nucleotide excision repair, translesion synthesis, and homologous 
recombination13 (Figure 3). The requirement of proteins from several different DNA 
repair pathways to complete ICL repair makes the coordination and crosstalk between 
transducer and effector proteins particularly important. Persistent ICLs can result in 
DSBs that are processed aberrantly by NHEJ. This results in the formation of 
chromosomal aberrations and radial chromosomes55. The cytotoxicity of ICLs is due to 
the fact that they covalently link opposing sides of the DNA helix and result in various 
levels of helix distortion depending on the chemistry of the ICL compound56. ICLs can 
result from exogenous sources such as the chemotherapeutic drugs mitomycin C (MMC) 
or cisplatin or from endogenous sources including reactive aldehydes and oxidized lipids 
that are a product of normal metabolism11. ICL-inducing agents represent a wide range of 
distortion severity in the DNA double helix and this characteristic has been shown to be 
one of the ways by which cells detect ICL lesions56. Although ICLs are commonly 
detected in S phase when replication forks collide with the ICL, cells are also able to 
repair ICLs by a replication-independent process that is less well-defined57 (Figure 4). 
Although many components of these pathways are conserved between yeast and higher 
organisms, vertebrates have evolved an additional network of >20 proteins specialized for 
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ICL repair, called the Fanconi anemia (FA) pathway11,58. 
 
     Replication-dependent ICL repair at the molecular level was described in a study 
using Xenopus egg extracts59. Replication-dependent repair is the most prevalent method 
by which ICLs are resolved and is restricted to the S and G2 phases of the cell cycle60. 
Repair is initiated when a replication fork collides with an ICL, resulting in the eviction 
of the CMG complex from the DNA60. The replication fork then proceeds to the -1 
nucleotides of the crosslinked bases and initiates removal of the ICL by NER proteins 
and the Fanconi anemia Pathway proteins FANCI and FANCD2, which are mono-
ubiquitylated by FANCL of the FA core complex60 (Figure 3). Activation of the E3 
ubiquitin ligase activity of FANCL is dependent on assembly of the entire core 
complex61. Without any one member of the core complex, ubiquitylation will not occur 
and the pathway will not be activated, resulting in the disease FA11. FA is a cancer 
predisposition disease in which the inability of the patient’s cells to repair ICL lesions 
results in progressive bone marrow failure along with the development of solid tumors 
and blood cancers62. Inactivation of any of the 20 plus proteins involved in the FA 
pathway results in development of the disease with varying degrees of severity depending 
on the FA protein affected11,62. Patients with FA have a short life expectancy, as there are 
no effective treatment options63. The activation of the FA complex recruits a toolkit of 
nucleases that act to “unhook” or remove the lesion from the DNA, resulting in a DSB. 
The nucleases involved in unhooking include SLX1, MUS81/EME1, and XPF/ERCCI, 
and these nucleases are tethered to SLX4, a critical scaffolding protein64. FAN1 has also 
been shown to act under certain conditions65. Although XPF is known to be the 3’ 
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nuclease that acts to unhook the ICL lesion (and has been shown to be able to act on the 
5’ side of the ICL), there still remains the possibility that there are other unidentified 
nucleases that could function on the 5’ side of the lesion64. After the ICL is unhooked, 
translesion synthesis polymerases REV1 or polymerase γ come in to bypass the 
remaining lesion and the damage is repaired by homologous recombination57.  
After its identification and initial characterization, the FANCD2 associated nuclease, 
FAN1, was thought to be the potential nuclease that could act on the 5’ side of ICL 
structures in the FA pathway thus acting with XPF in the unhooking step65–67. Although 
FAN1 was found to bind directly to FANCD2 and there was a decrease in cell survival 
when FAN1 depleted cells were treated with crosslinking agents, patients with deficient 
FAN1 develop a kidney disease called karyomegalic interstitital nephritis and not FA68. 
This could be due to the fact that FAN1 acts on an ICL resulting from a particular type of 
endogenous bifunctional reactive metabolite69,70. It is also possible that FAN1 has 
redundant function with other FA nucleases in addition to another role outside of FA 
repair. It is very important to note that although FAN1 was found in 2010, and has been 
shown to be able to unhook ICL structures in in vitro assays, the exact substrate of FAN1 
has likely not been identified. Thus, additional experimentation is required. 
Replication-independent repair is crucial for repairing ICL damage in post mitotic or 
rarely diving cells including neurons or stem cells60,71. Although replication-independent 
ICL repair has specific differences when compared to replication-dependent (classical) 
ICL repair, the main steps of the pathways are the same. Cells must act to recognize the  
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Figure from Ceccaldi, et al. 2016 (11).  
 
Figure 3. Fanconi anemia-dependent interstrand crosslink repair. Cooperation of 
Fanconi anemia, nucleotide excision repair, translesion synthesis and homologous 
recombination proteins in a common interstrand crosslink repair pathway. Stalling of 
replication forks on DNA interstrand crosslinks (ICLs) induces lesion recognition by the 
FANCM-FAAP24-MHF1-MHF2 complex (not shown) and subsequent recruitment of the 
Fanconi anemia core complex. UHRF1 (ubiquitin-like with PHD and RING-finger 
domains 1) might also be involved in lesion sensing. FANCM promotes an ATR (ataxia 
telangiectasia and RAD3-related) kinase-dependent checkpoint response, which in turn 
phosphorylates and activates multiple Fanconi anemia proteins. A consequence of 
activation of the Fanconi anemia core complex is the monoubiquitylation of the 
FANCD2-FANCI (FAND2-I) heterodimer, which is promoted by the ubiquitin ligase 
FANCL and its partner ubiquitin-conjugating enzyme E2 T (UBE2T). ICLs in the S 
phase of the cell cycle impede replication fork progression, and leading strands pause 20-
40 nucleotides away on either side of the ICL. Eviction of the replicative helicase CMG 
complex through action of breast cancer type 1 susceptibility protein (BRCA1) allows the 
approach of one replication fork to within one nucleotide of the ICL. Ubiquitylated 
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FANCD2 is directed to the ICL region, where it functions as a landing pad for the 
recruitment of several factors, including SLX4 and Fanconi-associated nuclease 1 
(FAN1), and coordinates nucleolytic incisions that are probably mediated by ERCC4 (a 
structure-specific endonuclease that also functions in nucleotide exicison repair) and 
possibly MUS81. Unhooking the DNA leaves the complementary strand, which is 
bypassed by translesion synthesis polymerases such as REV1 or DNA polymerase 
(REV3-REV7). Ligation restores an intact DNA duplex, which functions as a template 
for homologous recombination-mediated repair of the double-strand break (DSB). The 
DNA incisions create a DSB, which is further processed by nucleases such as CtBP-
interacting protein (CtIP), MRN (MRE11-RAD50-NBS1), exonuclease 1 (EXO1), and 
the helicase-nuclease complex BLM-DNA2 (Bloom syndrome protein-DNA replication 
ATP-dependent helicase/nuclease 2) that creates a single-stranded DNA (ssDNA) 
overhang. This ssDNA coated with replication protein a (RPA) is a substrate for RAD51-
mediated strand invasion promoted by BRCA2 and subsequent homologous 
recombination. The USP1-UAF1 (ubiquitin carboxyl-terminal hydrolase 1-USP1-
associated factor 1) complex deubiquitylates the FANCD2-I heterodimer and completes 
repair.  
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ICL damage, signal for recruitment of downstream repair proteins, and repair the lesion. 
Replication-independent ICL detection during transcription is limited to RNA 
polymerase II collision followed by recruitment of a collection of NER factors along with 
Cockayne Syndrome A and B (CSA and CSB)27,60. Lesions that result in more significant 
distortion of the DNA helix, such as cisplatin, require XPA, XPF, and XPG proteins 
while less distorting lesions such as MMC require action by XPC56,57. After lesion 
recognition and recruitment of additional factors through activation of the FA core 
complex, the lesion must be incised by nucleases. There is still much debate surrounding 
the ICL repair mechanisms that are highlighted in the pink box (left). Four steps are 
shown (left). Three distinct mechanisms can sense ICL lesions (indicated by a red line) 
(top): repair proteins recognizing distortion in the DNA helix (left column), a transcribing 
polymerase (middle column), or a replisome blocked by the lesion (right column). 
Recognition can occur through dedicated repair enzymes [nucleotide incision repair 
(NER) or mismatch repair (MMR)] or following collision during DNA transactions. 
Several nucleases are thought to participate in the incision steps (second row); however, 
their exact sites of action and which nucleases unhook the cross-linked base in 
replication-independent ICL repair are still debated (Figure 4). XPF/ERCCI is a likely 
candidate as it has been shown to cleave 5’ and 3’ of the ICL in vitro57,72. SNM1A has 
also been shown to act after the action of a 5’ endonuclease to digest through the 
crosslinked base resulting in a better substrate for downstream repair72. Furthermore, data 
suggests that SNM1A has also been shown to interact with CSB, a known component of 
replication-independent ICL repair27. It will be of interest to further explore the 
coordination between various nucleases involved in replication-independent ICL repair.  
 		 	 	18	
 
Figure from Williams et al. 2013 (71). 
 
Figure 4. Pathways of interstrand crosslink (ICL) repair. Replication-independent not 
defined. XPR/ERCC1, by analogy with NER, is thought to act 50 of the ICLs, whereas 
the 30 nuclease acting in replication-independent ICL repair (RIR) is not known (?). The 
Fanconi anemia (FA) pathway regulates the activity of nucleases in the replication-
dependent pathway. FANCM facilitates fork regression, whereas other FA proteins could 
recruit nucleases. Specific translesion synthesis nucleases participate in distinct repair 
pathways (third row): Polk and Polz in replication-independent repair and Rev1 and Polz 
in the replication-dependent pathway. More than one DNA polymerase could be involved 
in the repair of an ICL. Replication-dependent ICL repair generates a double-strand break 
(DSB) intermediate (bottom left), which is ultimately repaired via homologous 
recombination (HR).  
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ICL repair is also known to take place outside of replication or transcription and the 
proteins involved are predicted to be of MMR or NER pathways but this has not been 
definitively confirmed71.   
1.7 Fanconi anemia 
FA is a cancer predisposition syndrome that has varied clinical phenotypes but the 
hallmark of the disease is bone marrow failure that initiates early in life73 (Figure 5). FA 
patients have a much higher risk of solid tumors including squamous cell carcinomas and 
blood cancers such as myeloid leukemia11. The heterogeneity of physical manifestations 
of the disease is likely due to the fact that there are 20+ genes that can contribute to FA 
development74. Diagnosis commonly occurs after patients present with pancytopenia and 
are tested for sensitivity to crosslinking agents. The gold standard of FA diagnosis is to 
treat a sample of peripheral blood cells from the patient with crosslinking agents such as 
MMC or diepoxybutane (DEB) and analyze a metaphase spread for radials and other 
aberrations75. The inability to repair ICLs can result in replication fork stalling, which 
leads to replication fork collapse and subsequently single and double stranded breaks that 
create massive genomic instability in FA patients76. Although FA was first discovered 
over 90 years ago, there are still minimal effective treatment options beyond total bone 
marrow replacement and life expectancy for patients with FA hovers around 30-35 
years11. One unforeseen benefit of FA research was the improvement of bone marrow 
transplants in general68. Also understanding the FA pathway, in the context of ICL repair, 
will be helpful in further understanding various types of breast and ovarian cancer as  
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Figure from Fanconi anemia Research Fund. 
 
Figure 5. Fanconi anemia phenotypes. Patients with FA can present with a variety of 
phenotypes, the most common being abnormal blood cell counts. The genetic 
heterogeneity of the disease contributes to the phenotypic heterogeneity. FA patients may 
have any combination of these possible symptoms.   
 
 
 
 
 		 	 	21	
some protein factors that play a role in those diseases are also FA proteins77.  
1.8 FEN1 Structure-specific Nucleases 
Our discovery of SAN1, or Senataxin-associated nuclease 1, was based on a 
significant sequence similarity with the nuclease domains of a family of four other 
structure specific nucleases, including Flap endonuclease 1 (FEN1), Exonuclease 1 
(EXO1), Holliday Junction 5’ flap endonuclease (GEN1), and Xeroderma Pigmentosum 
G (XPG)78–80. Each member of the family has a highly conserved nuclease domain 
containing “N” (N-terminal) and “I” (internal) regions that constitute the active site of 
these proteins81. The N-terminal region or NH2 region binds DNA, while the Internal 
region coordinates two magnesium ions via its several cysteine and glutamate residues, 
ultimately helping tether the enzyme to the DNA through interactions with phosphate 
groups on the backbone81,82. These two critical nuclease domain components are also 
separated by a spacer region. FEN1 family members also display specific substrate 
preferences that correspond with the various DNA replication or repair pathways they act 
in (Figure 6). These substrate preferences can be largely attributed to various pockets on 
the surface of the enzyme adjacent to the active site that probe the environment 
surrounding the potential substrate and provide additional recognition80. The crystal 
structure of FEN1 bound to DNA and EXO1 bound to DNA have identified previously 
unknown commonalities between how members of this family of proteins bind and 
cleave specific DNA structures80,83 (Figure 6). FEN1 family members are regulated by 
post-translational modifications and through activating or inhibitory structural changes 
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caused by protein-protein interactions79,84. FEN1 family nucleases function in various 
aspects of DNA repair and metabolism and are critical for genomic stability.  
 
     FEN1 functions in several key replication and repair processes including Okazaki 
fragment processing, long-patch base excision repair, stalled replication fork rescue and 
telomere maintenance78. In addition to DNA replication and repair, FEN1 has been 
shown to degrade DNA during apoptotic DNA fragmentation. Apoptotic DNA 
fragmentation by endonucleases results in the generation of 150-180 base pair fragments 
of DNA85. Although the idea that a nuclease like FEN1 can play a role in DNA 
replication and also in the destruction of DNA through apoptotic DNA fragmentation 
may seem contradictory, these seemingly opposing actions of FEN1 can be attributed to 
the extensive network of FEN1 interacting proteins, cellular localization of the protein, 
and post-translational modifications79. As a nuclease on flap structures, FEN1 acts using 
a threading mechanism in which it first recognizes the free 5’ end of single-stranded 
DNA of a flap. The enzyme then moves down the single-stranded DNA region to the 
junction of single-stranded and double-stranded DNA and after binding, threads the DNA 
back through the enzyme for cleavage78. This interesting binding mechanism is the 
reason that FEN1 does not act on the single-stranded DNA resulting from processing 
Okazaki fragments and also explains the ability for FEN1 to act as an exonuclease86. 
Although FEN1 appears to have flap endonuclease activity, exonuclease activity, and gap 
endonuclease activity, it has been shown that the kcat/Km of flap endonuclease activity is 
significantly higher than of the other two types of nuclease activity exhibited by FEN183. 
Throughout other studies, FEN1 has been shown to interact with over 30 proteins, and  
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Figure from Williams, et al. 2011 (80). 
Figure 6. FEN1 family member substrate preferences and nuclease domain 
structure. (a) Structures of preferred substrates for FEN family members. Arrows 
indicate cleavage. FEN1 cleaves flap structures and is active during replication, EXO1 
acts on dsDNA to generate overhangs for HR, XPG acts on bubbles and other structures 
formed by UV and other damaging agents that are then repaired by NER, and GEN1 acts 
during HR to resolve Holliday Junctions (b) Structural comparison of FEN1 bound to 
DNA as compared to EXO1 bound to DNA. Purple: Arch region. Yellow: H2TH DNA 
binding motif. Green: Helical wedge. Orange: Specificity binding pocket for double-
stranded DNA bearing either a 3’ flap (FEN1) or a 3’ overhang (EXO1). 
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along with the post-translational modifications that regulate the function of FEN1, this 
nuclease has a significant scope of activity in global genome maintenance79,87,88. FEN1 is 
also regulated by subcellular localization and has been shown to move into the nucleus 
based on the cell cycle and stimuli from DNA damage signals89.      
EXO1 is an exonuclease that acts in several different DNA repair pathways including 
MMR, HR, and alt-EJ/SSA83,88,90. As the only nuclease to function during MMR, EXO1 
degrades long stretches of DNA where mismatches occur91. During HR, EXO1 functions 
as an end resection nuclease in which the 5’ end of double stranded DNA is resected in 
the 5’-3’ direction, generating long 3’ single-stranded DNA overhangs that are bound by 
RPA45,90. Although RPA is known to bind ssDNA to protect it from degradation and also 
serve as a docking point for other factors involved in DNA double-strand break repair, 
the relationship between EXO1 and RPA is not fully understood92. There have been 
reports of RPA inhibiting EXO1 activity and there are also reports of RPA stimulating 
EXO1 activity93,94. Further experimentation is needed to fully understand the 
complexities of the relationship between EXO1 and RPA.  
EXO1 often acts after initial processing by another nuclease, CtIP, and is activated by 
phosphorylation by the sensor kinase ATM. To stimulate nuclease activity during end 
resection, EXO1 can also form complexes with BLM, WRN, and RECQL1 helicases45,95. 
Of interest, EXO1 is a processive nuclease, giving it the capability to resect long stretches 
of dsDNA for homologous recombination. After homology-searching the sister 
chromatid, these overhangs then invade the double-stranded DNA region of the sister 
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chromatid resulting in D-loop formation and synthesis of new DNA96. As mentioned 
previously, end resection is the critical commitment step of HR. Thus, EXO1 is a highly 
important factor that acts to commit to HR44. In addition to exonuclease activity, EXO1 
also has flap endonuclease activity similar to FEN1 and can also act on RNA84. EXO1 
has also been shown to have a connection to familial colorectal cancer with EXO-1 
deficient patients having a poor prognosis97. In addition to the human cancer link, EXO-1 
knockout mice develop tumors, have decreased lifespan, and also have reproductive 
issues98.  
 
     GEN1 is a Holliday Junction resolvase endonuclease that acts with MUS81/EME1 to 
process Holliday Junctions, or four-way DNA structures resulting from HR48. GEN1 
possesses the same nuclease domain as other members of the FEN1 family and regulates 
cleavage of HJ structures through an initial dimerization step49. After dimerization on the 
DNA junction, the GEN1 dimer makes two nicks in the joined DNA allowing for further 
downstream processing and repair99. Correct resolution of Holliday Junction structures is 
important for proper DNA separation and maintaining genomic integrity100. Interestingly, 
GEN1 has a largely disordered C-terminal domain making purification of the full-length 
protein challenging until recently99. GEN1 also possesses a unique region called a 
chromodomain, which acts as an additional DNA binding region49. Chromodomains have 
been well established in chromatin-modeling enzymes but had not been discovered in a 
nuclease until GEN1. The importance of the chromodomain in the function of GEN1 is to 
provide additional DNA binding support to the GEN1 active site to position the DNA in a 
way that allows for GEN1 to properly cleave the HJ substrate49. GEN1 is also the only 
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member of the FEN1 family to have such a region, making it a unique component of 
GEN1 substrate recognition and processing78. 
 
     XPG is an NER nuclease that cleaves 3’ to DNA damage commonly resulting from 
exposure to UV light88. In addition to XP, mutations in XPG can lead to Cockayne 
syndrome (CS) which manifests as skeletal, neurological, and developmental disorders. 
Studies have shown that in high salt conditions XPG exists as a monomer. In lower salt 
conditions, XPG can dimerize and through additional experimental evidence it has been 
shown that XPG dimers often acts in complex with other protein factors101.  
1.9. Research Objectives 
Although there have been major advances in understanding the various ways by which 
cells detect and repair ICLs, there are still fundamental gaps in our understanding of the 
mechanism of ICL repair throughout various phases of the cell cycle (Figure 4). 
Replication-dependent ICL repair through activation of the FA pathway is the most well-
characterized method by which ICLs are detected and excised from the genome. 
However, this pathway is only active during S and G2 phases of the cell cycle63. The 
steps and pathway components of replication-independent ICL repair, or Fanconi anemia-
independent ICL repair, on the other hand, are much less clear. Recent advances in 
understanding the ways by which cells can detect ICLs outside of replication, either 
through MMR-dependent mechanisms or through transcription-coupled ICL repair, are 
significant but there are still many unknowns56,60,72. Identifying the molecular 
mechanisms that orchestrate the repair of every DNA damage event that occurs in cells 
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every day is critical in not only understanding how these pathways are regulated but also 
how we can modulate them to decrease disease burden of patients afflicted with ICL 
repair protein diseases including FA, XP, and CS. The lack of understanding of the 
crossover between pathways by which ICLs can be repaired during each phase of the cell 
cycle is reflected by the lack of treatment options for people with these diseases and thus 
there is an urgent need to progress this area of research.  
This dissertation aims to characterize SAN1, which is a completely novel component 
of ICL repair and the first nuclease involved in interstrand crosslink repair to be 
discovered since FAN1 was identified in 201065,67. Preliminary characterization of the 
protein as a nuclease raised many questions about the potential involvement of SAN1 in 
DNA repair. Although there are many known nucleases that act in the various DNA 
damage response pathways there are still unknown components of these pathways that 
may act under certain conditions or have redundancy with other known nucleases. There 
are also significant gaps in the understanding of the molecular mechanisms of replication-
independent ICL repair pathways. This dissertation work builds upon the initial discovery 
of the previously uncharacterized protein, SAN1, and explores our understanding of the 
unique nuclease activity of the protein. This work also describes the complex relationship 
between the structure and function of a newly identified member of the FEN1 family. 
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2.1 Abstract 
 
     As the most recently discovered member of the FEN1 family of structure-specific 
nucleases, SAN1 has significant similarities and unique differences when compared to 
other family members. As an exonuclease, SAN1 is able to digest 2 or 7 nucleotide 
fragments from ssDNA structures of larger than 25 nucleotides and requires a free 5’ end 
of DNA for loading onto the DNA and subsequent cleavage. Also of note, SAN1 cleaves 
ssDNA structures with different efficiencies generating a distinct laddering pattern for 
each sequence. SAN1 has a conserved nuclease domain that is homologous to other 
FEN1 family members, a unique C-terminus that was previously uncharacterized but has 
been shown to be required for nuclease activity, and an internal repeat region that is not 
required for nuclease activity. SAN1 preferentially cleaves DNA with splayed arm 
structures but will also cleave 5’ ssDNA flaps, albeit with less efficiency than single-
stranded DNA or splayed arm structures. In contrast to other FEN1 family members, 
SAN1 does not cleave nicked or gapped regions of DNA efficiently. Taken together, 
these results describe the characterization of a protein that was previously completely 
uncharacterized and provide evidence for a unique member of an already diverse 
nuclease family.  
 
2.2 Introduction 
 
 Members of the FEN1 family of structure specific nucleases have roles in many 
aspects of DNA replication and repair and are thus critical components of genome 
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integrity102. Although each member of the family acts on different substrates, the catalytic 
activity of these nucleases is very similar. FEN1 family members have a highly 
conserved nuclease domain with the N (NH2) and I (Internal) regions of the nuclease 
domain separated by a spacer region88. The N region is critical for DNA binding and the I 
region binds two Mg2+ ions that ultimately stimulates substrate binding and subsequent 
DNA cleavage83. EXO1 and GEN1, for example, have been shown to resect double-
stranded DNA for strand invasion during HR and to resolve Holliday Junctions that result 
after HR, respectively81,99. XPG is involved in processing damage repaired by NER and 
FEN1 is involved long-patch BER101. In recent years, our understanding of the nuclease 
activity of each of these unique enzymes has increased exponentially. Until SAN1, the 
novel FEN1 family nuclease described in this study, there had been, to date, no evidence 
of involvement of any other FEN1 family members in ICL repair.  
 
Our knowledge of the DNA repair machinery remains incomplete, and additional 
nucleases might exist for removal of specific lesions. In this study we identified an 
uncharacterized protein that contains an N-terminal domain closely related to the FEN1 
family of structure-specific nucleases. This protein is not a known component of any 
DNA repair complex, but we now report that it is a 5’exonuclease for single-stranded 
DNA, and is required for the cellular response to ICLs.  
 
2.3 Results and Discussion 
Previous work identified an uncharacterized protein with sequence homology to the 
FEN1 family of structure-specific nucleases (Figure 7a), which we named SAN1, or 
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Senataxin-associated nuclease 1. The protein shares with the other members of the FEN1 
family (FEN1, EXO1, XPG, GEN1) conserved acidic residues that constitute the active 
site of these proteins (Figure 7b). Using the Robetta server, these acidic residues were 
modeled to the crystal structure of FEN1 (Figures 7c, d). Acidic active site residues are 
present in the N and I regions of the nuclease domains of this family of proteins and are 
responsible for coordinating substrate binding and metal cofactor binding along with 
catalyzing the reaction. Using these modeling data the conserved aspartic acid 90 residue 
was mutated to alanine generating a D90A mutant of SAN1. The D90A point mutant of 
SAN1 was hypothesized to eliminate catalytic activity. In addition to the conserved 
FEN1 nuclease domain, SAN1 also has a unique internal repeat region, and a C-terminus 
that is conserved among SAN1 homologs but is of unknown function (Figure 7a). The 
internal repeat region consists of about twelve 15- amino acid repeat motifs with the 
general sequence of QEVPM that are predicted to be largely unstructured and are not 
found in any other protein (Figure 7a).  
To determine if SAN1 was able to act as a nuclease, WT SAN1 or D90A SAN1 were 
tested for activity against 5’ 32P labeled ssDNA or 3’ 32P labeled ssDNA substrates after 
affinity purifying the FLAG-tagged protein from mammalian 293T cells (Figure 8a). 
Interestingly, when WT SAN1 is incubated with a 5’ 32P labeled ssDNA oligonucleotide 
and the results are visualized on a denaturing urea gel, it is clear that SAN1 cleaves 
ssDNA liberating a ~3 nucleotide and ~7 nucleotide 32P labeled fragment from the DNA 
(Figure 8b). Importantly, the D90A SAN1 mutant showed no activity on the 5’ or 3’ 32P 
ssDNA oligonucleotide confirming that nuclease activity can be completely abolished by 
a single point mutation. Incubating WT SAN1 with 3’ 32P ssDNA in a nuclease assay 
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Tim Errington 
Figure 7. SAN1 homology to the FEN1 family of structure specific nucleases. (a) 
Schematic of the domain architecture of SAN1 including the N-terminal nuclease 
domain, central repeat region of around twelve 15-amino acid repeats, and conserved C-
terminus. (b) Sequence alignment of nuclease domains of human SAN1, EXO1, FEN1, 
GEN1 and XPG. Identical and similar residues are in bold. Conserved acidic residues in 
the active site are highlighted in red.  (c) Modeling of conserved carboxylates in active 
site of SAN1 (light blue), using the Robetta server (http://robetta.bakerlab.org) and the A. 
fulgidus FEN1 structure (PDB 1RXW) (green) as template. Residue highlighted by red 
box is the aspartate mutated to make D90A. (d) The nuclease domain sequence of SAN1 
was submitted to the Robetta server (http://robetta.bakerlab.org ) and the server found a 
confident match to the A. fulgidus FEN1 protein, whose structure was used as a template 
for comparative modeling. SAN1 model (light blue) and FEN1 template (PDB 1RXW) 
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(green) were aligned and visualized with the PyMol Molecular Graphics System, Version 
1.3 Schrödinger, LLC. 
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generated a ladder pattern in which WT SAN1 cleaves the 50 nucleotide sequence down 
to about 25 nucleotides but will not cut further (Figure 8b). In contrast to EXO1 which 
readily resects dsDNA during HR, SAN1 is not active on a dsDNA structure (Figure 8c). 
SAN1 also showed activity against a 3’ 32P ssDNA oligonucleotide of 50 nucleotides, 
cleaving the sequence down to about 25 nucleotides but showed no activity against a 25 
nucleotide sequence (Figure 8d). Together these results provide an initial understanding 
of the unique nuclease function of SAN1. SAN1 has homology to the FEN1 family of 
structure specific nucleases and WT SAN1 exhibits 5’ exonuclease activity on ssDNA of 
greater than 25 nucleotides only. D90A SAN1 exhibits no detectable nuclease activity, 
providing evidence that the single-point mutation of WT SAN1 is sufficient to abolish 
nuclease activity and to confirm that the nuclease activity observed is attributable to 
SAN1. 
 
After the initial discovery of SAN1 as a new member of the FEN1 family of structure-
specific nucleases and that SAN1 is able to act as a nuclease on ssDNA substrates of 
larger than 25 nucleotides (Figure 8), a key goal was to further investigate the properties 
of this novel enzyme. A first step was to confirm that the nuclease activity is endogenous 
to SAN1 rather than to a contaminating cofactor, using recombinant protein expressed in 
bacteria. 
A tetracycline-inducible WT or D90A SAN1 construct transformed into BL21 DE3 
RIPL cells was used to express SAN1. These cells allow increased expression of 
mammalian proteins due to the expression of tRNAs of amino acids more commonly 
found in mammalian proteins. Mouse SAN1 (mSAN1) was selected instead of human  
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Tim Errington 
FIGURE 8. SAN1 acts as an exonuclease on 5’ ssDNA. (a) Schematic of WT SAN1-
FLAG or D90A SAN1-FLAG purification from 293T cells. Nuclease assays with affinity 
purified WT SAN1-FLAG or D90A SAN1-FLAG and various substrates (b) 5’ 32P 
labeled 50 nucleotide ssDNA as compared to 3’ 32P labeled 50 nucleotide ssDNA (c) 3’ 
32P labeled 50 nucleotide ssDNA as compared to 3’ 32P labeled 50 nucleotide dsDNA (d) 
3’ 32P labeled 50 nucleotide ssDNA as compared to 3’ 32P labeled 25 nucleotide ssDNA.
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SAN1 (hSAN1) because of its smaller size. Although the nuclease domains are highly 
similar mSAN1 possesses fewer internal repeat motifs than hSAN1 (Figure 9a). 
 
Expression of the	mSAN1 protein was induced with tetracycline at 18°C overnight 
followed by lysis using a French Press and purification of the cell lysate over a Strep-
Tactin column with desthiobiotin elution (Figure 9b). To verify mSAN1 expression and 
purification, an SDS gel of WT mSAN1 and D90A mSAN1 were stained with Coomassie 
brilliant blue and the signals were compared to BSA standards (Figure 9c). WT mSAN1 
and D90A mSAN1 were expressed, captured, and eluted from the Strep-Tactin beads 
(Figure 9c).  
 
Activity of the recombinant mSAN1 was tested on 60 nucleotide ssDNA substrates X1 
and X4 (shown previously in Figure 8 and listed in Appendix II). Recombinant WT 
mSAN1 or D90A mSAN1 was incubated with radiolabeled probe and a Start Buffer 
containing magnesium (a vital cofactor for FEN1 family proteins) for 2 hrs at 37°C. 
Samples were then analyzed on a denaturing urea gel and products were detected by 
autoradiography. As shown in Figure 9d, WT mSAN1 is able to cleave both X1 and X4 
substrates and the D90A mSAN1 is unable to cleave either substrate. This result supports 
our proposal that SAN1 is indeed responsible for the nuclease activity observed on 
ssDNA substrates.  
 
However, although bacterial expression was effective in providing additional support 
that the nuclease activity on ssDNA substrates was specific to SAN1, the method  
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FIGURE 9. Recombinant mouse WT SAN1 shows similar nuclease activity to 
human WT SAN1. (a) Schematic of human SAN1 compared to mouse WT SAN1 
(mSAN1). (b) Bacterial purification scheme of mSAN1 produced from tetracycline 
inducible BL31 DE3 (RIPL) cells. (c) Murine SAN1 was expressed with a C-terminal 
Strep tag in E. coli and purified over Strep-Tactin beads. Purified protein (0.2 ug) was 
analysed by PAGE and stained with Coomassie brilliant blue. Arrow shows mSAN1 
expected size of 100 kD. (d) Synthetic 50-mer oligonucleotides were 5’-labeled with 32P 
and incubated with mSAN1 for 120 min. Products were separated by PAGE and 32P-
fragments were detected by autoradiography (see Appendix II for sequences).  
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produced only a small quantity of protein that was unstable in solution, and thus was not 
ideal for further characterization of the nuclease profile of SAN1. To address this I 
utilized a two-step purification system of WT SAN1 or D90A SAN1 purified from 293T 
cells, described in Figure 10a. To further confirm that the human SAN1 purified from 
transfected 293T cells is an active nuclease, I developed a two-step purification scheme 
using the SAN1-/- HeLa cell line stably expressing SAN1 SSF (Strep-Strep-FLAG) tag. 
SAN1-/- HeLa + SAN1 SSF cells were lysed and centrifuged, and the soluble fraction of 
the cell lysate was harvested. The soluble fraction was then incubated with Strep-Tactin 
beads, washed three times, and eluted with desthiobiotin for the first round of 
purification. The elution from the Strep-Tactin beads was then incubated with FLAG 
beads, washed three times, and eluted with FLAG peptide (Figure 10a). Fractions from 
each wash and elution step were saved for silver stain analysis and western blot analysis 
(Figures 10b, c). The major protein band eluted from each affinity purification step 
corresponded to the expected molecular weight of hSAN1 (150 kD). FLAG antibodies 
readily detected a protein of 150 kD in the elution fractions, which corresponds to 
hSAN1, and the wash fractions had no detectable SAN1 (Figure 10c).  
 
To quantify nuclease activity, I developed a spin assay in which the affinity purified 
SAN1 was incubated with a 5’ 32P labeled probe before spinning the reaction through a 
Qiagen Nucleotide Removal Column. Cleaved product, which consists of 2-7 nucleotide 
32P labeled fragments, is eluted from the column, while the substrate (50 nucleotides) is 
retained (Figure 10f). Elution fractions 1 and 2 (E1 and E2) showed a high concentration 
of radiolabeled product, indicating that the fractions that correspond to SAN1 by western  
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FIGURE 10. Two-step affinity purified hWT SAN1 shows nuclease activity in spin 
assay. (a) Schematic of double-affinity Strep-FLAG tag purification for human SAN1 
WT and SAN1 DA. (b) Silver stained fractions from the purification where “W” denotes 
Wash steps and “E” denotes Elution steps for the Strep and FLAG IPs. Arrow shows 
human SAN1 WT (expected size 150 kD) and asterisks show FLAG antibody heavy and 
light chains. (c) Top panel shows immunoblot of fractions from two-step purification of 
SAN1 where arrow shows SAN1 (expected size 150 kD), detected using mouse M2 anti-
FLAG-antibody. Bottom panel shows corresponding filter spin nuclease assay. (d) 50 
nucleotide X4 was 5’ 32P labeled and incubated with RPA as a positive control or 
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increasing concentrations of SAN1 D90A (catalytically inactive). Samples were analyzed 
on a native gel and exposed to X-ray film. (e) Using the filter spin assay, initial rates of 5’ 
32P-labeled X4 hydrolysis were measured at different substrate concentrations. Line was 
fitted using Prism software, assuming Michaelis-Menten kinetics. (f) Spin nuclease assay. 
Affinity purified WT SAN1 is added to a 5’ radiolabeled probe (50nt) before being added 
to a Qiagen Nucleotide Removal Column. Cleaved substrates will be present in the 
elution while uncleaved substrates will remain bound to the filter. 
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blot also have nuclease activity against ssDNA (Figure 10c). These data, combined with 
the recombinant SAN1 protein purification and corresponding nuclease activity, confirm 
that the nuclease activity observed in our assays can be attributed specifically to the 
SAN1 nuclease, and not to any contaminating protein.  
 
To determine if the D90A SAN1 point mutant, used as a negative control, was able to 
bind DNA, affinity purified D90A SAN1 was tested in a mobility shift assay (EMSA).  
The protein was labeled with 32P-ssDNA in binding buffer and analyzed by native gel 
electrophoresis. As a positive control, the single-stranded DNA binding protein RPA was 
used (Figure 9d). As shown in Figure 10d, there is an upward shift up in the location of 
the visualized radiolabeled ssDNA substrate (similar to RPA) with increasing 
concentrations of D90A SAN1. These data demonstrate that the point mutation in Asp90 
abolishes catalytic activity without disrupting the structure of the nuclease.  
 
I next examined whether the kinetic properties of SAN1 nuclease activity were similar 
to those of other FEN1 family members. Using the filter spin assay and affinity purified 
WT SAN1, initial rates of 5’ 32P-labeled X4 hydrolysis were measured at different 
substrate concentrations. Affinity-purified hSAN1 was used for this assay and the protein 
concentration was quantified using Coomassie brilliant blue stain of samples as compared 
to BSA controls of known concentration (Figure 11a). Importantly, this assay was 
completed during the linear phase of the nuclease reaction as shown in Figure 11b. The 
line was fitted using Prism software assuming Michaelis-Menten kinetics. These data 
demonstrate that SAN1 has a similar kinetic profile to human EXO1 with a Km of 460  
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Tim Errington – panel E 
FIGURE 11. SAN1 purification from mammalian cells and substrate and cofactor 
characterization. (a) Affinity purified hWT SAN1 and hDA SAN1 from 293T cells as 
compared to BSA standards visualized by Coomassie brilliant blue stain. Arrow shows 
hSAN1 expected size of 150 kD. (b) Time course of SAN1 WT in linear range of the 
nuclease reaction with ssDNA X1 as a substrate. (c) Time course of 5’ 32P-labeled 
ssDNA X1 digest. (d) WT SAN1 was incubated with increasing concentrations of various 
metal ions and assayed for activity against a 5’ 32P ssDNA substrate (e) V, WT, or D90A 
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SAN1 was incubated with ssDNA 3’ 32P ssDNA probes (sequences showed below). X4 
and X1 are random sequences and X5 is a homopolymer of T’s of the same length.  
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nM +/- 72 and a kcat of 10.6 min^-1 +/- 0.8 83 (Figure 10e). To test whether larger, 
intermediate products are formed during the SAN1 nuclease assay, I performed a time 
course experiment where radiolabeled ssDNA was incubated with WT SAN1 over a time 
course from 0 min to 60 min. From the results of this assay, it was clear that no 
intermediate products are produced at short incubation times (Figure 11c). To determine 
whether SAN1 utilizes Mg2+ or another cation as the preferred metal catalytic cofactor, 
various divalent metal ions were titrated into the nuclease reaction with affinity purified 
SAN1 and the nuclease activity on a ssDNA substrate was measured (Figure 11d). After 
separating the products on a denaturing urea gel and imaging the products formed using 
autoradiography, I observed the largest increase in radiolabeled product in the reaction 
where increasing concentrations of Mg2+ were added (Figure 11d). Other members of the 
FEN1 family also prefer Mg2+ as the metal cofactor, providing further evidence that 
although SAN1 has differences when compared to members of the family, catalytically 
the enzymes function very similarly. 
When SAN1 is incubated with a 3’ 32P labeled ssDNA probe, it generated products 
that resemble a ladder. To probe this result deeper, SAN1 nuclease activity was tested 
against several additional ssDNA oligonucleotides with varying sequence (Figure 11e). 
X1 and X4 are 50 nucleotide ssDNA sequences and figure X5 is a homopolymer of T’s. 
From these assays it was clear that SAN1 cleaves different sequences with different 
efficiencies and will not cut a homopolymer of T’s. A homopolymer of T’s was used over 
other sequences as other homopolymers form higher order structures that would block 
SAN1 nuclease activity. From these data, I propose that SAN1 may have some sequence 
preference in that it more easily cuts some sequences over others but to date I do not 
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know the full extent of what this varying substrate preference means biologically for the 
nuclease.  
 After confirming that the nuclease activity observed in previous assays was specific to 
SAN1, it was important to understand how SAN1 recognized and bound its preferred 
substrate. To address how SAN1 recognized substrates, and specifically, single-stranded 
DNA I designed a modified oligonucleotide. 3’ 32P labeled X4 (a known substrate of 
SAN1) and 3’ 32P labeled X4 modified with a 5’ biotin covalently linked to the 
oligonucleotide (Figure 12a) were utilized in a nuclease assay. The ability of SAN1 to 
cleave 2-7 nucleotides from the 5’ end of ssDNA left us with the question of whether 
SAN1 was truly acting as an exonuclease (requiring a free 5’ end of DNA) or if it was 
acting as an endonuclease (able to bind and cleave in the middle of the sequence). 
Members of the FEN1 family have both endonuclease and exonuclease activity, so 
determining how SAN1 recognizes and cleaves substrates was important to 
understanding what types of structures it might recognize in vivo. The results from this 
assay show that WT SAN1 cleaves the 3’ 32P labeled un-biotinylated substrate but does 
not cleave the 3’ 32P labeled 5’ biotinylated substrate (Figure 12a). The 5’ biotin blocks 
SAN1 from recognizing the free 5’ phosphate of the ssDNA and thus blocks all activity, 
confirming that SAN1 acts as an exonuclease and likely requires a free 5’ end of DNA 
for binding.  
After determining that SAN1 requires a free 5’ end to recognize potential substrates, it 
was crucial to further characterize additional SAN1 substrates, including structures that 
could be regular substrates of nucleases during DNA replication or repair. The first 
structure tested was an overhang structure where 20 nucleotide of ssDNA was followed  
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FIGURE 12. SAN1 cleaves 5’ ssDNA substrates including splayed arm and flap 
structures. (a) Affinity-purified FLAG-SAN1 WT or D90A from 293T cells incubated 
with 5’ biotinylated X4 and unbiotinylated X4 (b) Affinity-purified FLAG-SAN1 WT or 
D90A from 293T cells incubated with 40 nucleotide ssDNA versus a 20 nucleotide 
ssDNA 5’ overhang followed by 20 bp of dsDNA (c) Affinity-purified FLAG-SAN1 WT 
or D90A from 293T cells incubated with dsDNA oligonucleotides with an internal nick 
or gap; (d) FLAG-tagged SAN1 WT or D90A was incubated with 5’ 32P labeled splayed 
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duplex, 3’ flap, or 5’ flap structures for 2 hrs at 37°C. Products were separated by PAGE 
and 32P-fragments were detected by autoradiography (see Appendix II for sequences) (e) 
SAN1 WT or SAN1 DA incubated with splayed duplex, 3’ flap, 5’ flap, and replication 
fork structures where the bottom strand (B) is 5’ 32P labeled. (f) Affinity-purified FLAG-
SAN1 WT or -D90A from 293T cells incubated with variants of ssDNA oligonucleotide 
X1 with 20 Ts 5’ and 3’ to 20 nts of X1, or a tract of 20 Ts bounded by two 20 nucleotide 
sections of the X1 sequence all for 2 hrs at 37°C. Substrates were 3’ 32P labeled. (g) 
Affinity purified FLAG-tagged WT or DA SAN1 from 293T cells was incubated 5’ 32P 
labeled Holliday Junction structures and products were separated by denaturing gel 
electrophoresis and 32P fragments were detected by autoradiography. 
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by 20 base pairs of dsDNA, generating a 20 nucleotide overhang of 5’ ssDNA (Figure 
12b). As the ssDNA length requirements for SAN1 to cleave are greater than 25 
nucleotide, I predicted that this ssDNA overhang of 20 nucleotide would not be cut by 
SAN1. Other members of the FEN1 family including FEN1, XPG, and GEN1 recognize 
ssDNA/dsDNA junctions and thus it may be possible that SAN1 recognizes a similar 
type of structure. The results for this assay are shown in Figure 12b where WT SAN1 is 
active on the 40 nucleotide ssDNA substrate and displays some activity on the 20 
nucleotide overhang structure but significantly less activity than on the ssDNA substrate. 
Although SAN1 was partially able to cleave the 5’ 20 nucleotide ssDNA overhang, this is 
likely not the ideal substrate for the SAN1 nuclease as the nuclease activity observed on 
the overhang substrate was significantly less than the activity observed previously on 
ssDNA substrates. 
 The next potential SAN1 substrates that were tested were a nick structure and a gap 
structure. Nicks arise often in DNA replication and repair and FEN1 and EXO1 are both 
able to cleave nicked and gapped structures49,83. Nicks and gaps can arise as a product of 
DNA damage or as a DNA repair intermediate that must be processed by additional 
nucleases and ligases to repair the lesion. A nick in the DNA is formed when the 
phosphate backbone is cleaved but there are no missing bases. A gap, on the other hand, 
is a structure that can be one missing base to several missing bases. The assay in Figure 
12c shows WT or D90A SAN1 tested against a nicked structure or a single-base gap 
structure, and it is clear that SAN1 does not cleave nick or single-base gap structures. 
This is a very interesting departure in activity from other members of the FEN1 family 
and sets the nuclease cleavage capabilities of SAN1 apart from the nuclease activity of 
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FEN1 and EXO1.    
 After determining that SAN1 does not cleave nicks and gaps like other members of the 
FEN1 family, we then tested several other substrates that are known to be cleaved by 
FEN1, EXO1, XPG, and GEN1. A splayed arm, 5’ flap, 3’ flap, and replication fork 
structures with the top strand of DNA 5’ 32P labeled or the bottom strand of DNA 5’ 32P 
labeled were tested by nuclease assay (Figures 12d, e). When the top strand was 5’ 32P 
labeled and the entire structure was incubated with WT SAN1 I observed cleavage of the 
splayed arm and 5’ flap structures but not the 3’ flap or replication fork structures (Figure 
12d). It should be noted that the splayed arm was more efficiently cleaved than the 5’ flap 
structure. When the bottom strand of the DNA was 5’ 32P labeled there was no detectable 
nuclease activity confirming previous results that showed that SAN1 is not active on 
dsDNA (Figure 11e). FEN1 cleaves splayed arm and flap structures readily and also 
EXO1 is able to cleave splayed arm and flap structures with less efficiency than FEN1.  
 In addition to determining whether SAN1 was active on replication and repair 
structures, it was of interest to further understand if SAN1 has a sequence recognition 
component of substrate binding. Utilizing the original data showing that SAN1 requires 
longer than 25 nucleotides of ssDNA to cleave the substrate as a tool, additional 
sequences were generated. Originally it was shown that SAN1 would not cut a 25 
nucleotide sequence of ssDNA but would cut a 50 nucleotide sequence of ssDNA down 
to about 25 nucleotides. Two different sequences were designed: one with 20 nucleotides 
of regular sequence (with A, T, C, G bases) followed by 20 nucleotides of Ts only, 
followed by 20 nucleotides of regular sequence and the other sequence with 20 
nucleotides of Ts, 20 nucleotides of regular sequence, followed by 20 nucleotides of Ts. 
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If SAN1 is not recognizing the entire stretch of DNA, but also requires greater than 25 
nucleotide of sequence to bind I predicted that SAN1 would be able to cleave only one of 
these two oligonucleotide sequences. Strikingly, SAN1 was able to cleave the 3’ 32P 
labeled oligonucleotide with 20 nucleotide of internal Ts but not the flanking Ts 
oligonucleotide (Figure 12f). This result supports a model in which SAN1 recognizes the 
initial sequence (up to about 20 nucleotides) for binding and cleavage and the sequence 
following is unimportant.   
 After determining that SAN1 cleaves splayed arm structures preferentially over other 
tested structures, I tested two other known FEN1 family substrates that also happen to be 
DNA repair intermediates. The first was a Holliday Junction, which is a four-stranded 
DNA structure that results from homologous recombination and must be repaired by 
enzymes, such as the GEN1 resolvase, for complete DNA repair. As shown in Figure 
12g, SAN1 did not cleave the Holliday Junction structure irrespective of which strand of 
the four-stranded DNA structure was 32P labeled. It is interesting to note that SAN1 does 
not cleave this specific HR intermediate (the HJ), making the nuclease activity of SAN1 
unique from GEN1. In a previous experiment, SAN1 nuclease activity was also tested 
against a bubble structure, which is a known substrate of another FEN1 family member, 
XPG. SAN1 was unable to cut the bubble structure (data not shown). Taken together, 
these results provide evidence for SAN1 having a very intriguing substrate recognition 
scheme, cleavage activity, and limit the pathway possibilities of the role of SAN1 as a 
nuclease in vivo.  
 These results along with the initial enzymatic data on SAN1 provide evidence that it is 
a unique nuclease. SAN1 acts as a 5’ ssDNA exonuclease on substrates longer than 25  
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FIGURE 13. SAN1 acts as an exonuclease on 5’ ssDNA structures. SAN1 binds 
ssDNA substrates greater than 25 nucleotide and cleaves from the 5’ end. SAN1 requires 
a free 5’ end of ssDNA for activity and after binding SAN1 cleaves 2-7 nucleotide from 
the 5’ end of DNA. SAN1 is not a processive nuclease and falls off after cleaving but 
may be able to rebind additional substrates.  
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nucleotides and requires a free 5’ end of DNA to bind (Figure 13). SAN1 cleaves 2 or 7 
nucleotide fragments from the 5’ end of ssDNA including splayed arm structures and 5’ 
flaps. I have also shown that SAN1 utilizes Mg2+ as its metal cofactor, like other FEN1 
family members, and may be able to fall off of DNA and rebind to initiate another 
cleavage event creating the laddering pattern of products seen after ssDNA substrates are 
3’ 32P labeled (Figure 13). 
 
 
 To understand how the various domains of SAN1 contribute to substrate specificity or 
regulation of the nuclease activity, several deletion mutants were designed. The nuclease 
domain of SAN1 is homologous to other members of the FEN1 family. However, other 
family members do not have the same internal repeat region or C-terminus of SAN1 that 
are of unknown function. As the C-terminus of SAN1 is conserved amongst species that 
have SAN1, I predicted that this region of the protein may be important for regulating 
nuclease activity, substrate recognition or a potential protein-protein interaction. An N-
terminal FLAG-tagged nuclease domain and a C-terminal Myc-tagged SAN1 C-terminus 
mutant were developed using Myc-RhoA as a negative control (Figure 14a). The N-
terminal FLAG-tagged nuclease domain and the C-terminal Myc-tagged SAN1 C-
terminus were co-expressed in 293T cells. The lysates were then immunoprecipitated 
with anti-FLAG M2 beads, and the results were analyzed by immunoblot (Figure 14b). 
The Myc Input membrane was re-exposed for a longer time to detect Myc-SAN1 C-
terminus as it showed a very low expression level alone. This observation could be the 
result of the N-terminal and C-terminal interaction providing structural stability to each 
domain and thus when the C-terminus is expressed alone a significant portion of it is 
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degraded as the mutant is unstable alone. Interestingly, the SAN1 C-terminal domain but 
not Myc-RhoA is co-precipitated with the nuclease domain providing evidence that the 
SAN1 C-terminus and N-terminus interact by co-immunoprecipitation (Figure 14c).   
 
After determining that the nuclease domain of SAN1 and the C-terminus interact by 
Co-IP, it was important to understand if this interaction was required for nuclease 
activity. To test this, an N-terminal/C-terminal fusion protein of SAN1 called ∆Repeats 
and an N-terminal/Repeat region fusion protein called ∆Cterminus were produced in 
293T cells and affinity purified (Figure 14d). The repeat region was hypothesized to 
function as a flexible linker to allow the N-terminus and C-terminus of SAN1 to interact 
for substrate recognition or activation of the nuclease domain. Each construct was 
overexpressed, immunoprecipitated with FLAG beads and analyzed by western blot to 
confirm that both deletion mutants were expressed and eluted efficiently (Figure 14e). 
The purified deletion mutants were then tested for nuclease activity against 5’ 32P labeled 
ssDNA using the filter spin assay described previously. We observed that the ∆Repeats 
mutant showed similar activity to WT SAN1 while the ∆Cterminus mutant showed no 
nuclease activity similar to D90A SAN1 (Figure 14f).  
 
Taken together, these results characterize a novel nuclease that shares some 
similarities with other FEN1 family members but also appears to have striking substrate 
and structure/function regulation differences. SAN1 acts as a 5’ ssDNA exonuclease and 
requires a free 5’ end of ssDNA to bind and cleave substrate. SAN1 will only cleave 
ssDNA substrates greater than 25 nucleotide but if the ssDNA is part of a larger structure, 
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Figure 14. SAN1 C-terminus is required for nuclease activity. (a) Schematic of SAN1 
deletion mutants used in b, c  (b) Schematic of SAN1 deletion mutant expression and 
purification from 293 T cells (c) The N-terminal FLAG-tagged nuclease domain was co-
expressed in 293T cells with C-terminal Myc-tagged SAN1 C-terminus, or Myc-RhoA as 
a negative control. Lysates were precipitated with anti-FLAG M2 beads and analyzed by 
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immunoblot. The Myc Input membrane was re-exposed for a longer time to detect Myc-
SAN1 C-terminus. The SAN1 C-terminal domain but not RhoA is co-precipitated with 
the nuclease domain. (d) Schematic of SAN1 deletion mutants used in e, f (e) 
immunoblot of WT, DA, ΔRep and ΔC-term proteins purified from 293T cells (f) tested 
for nuclease activity against 5’ 32P labeled ssDNA using the filter spin assay (N=2, error 
bars show range) 
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for example a splayed arm or 5’ flap structure, it will act on the free 5’ end. After 
showing that the N-terminus and C-terminus interact by Co-IP and this interaction is 
required for nuclease activity, I propose a new model that combines all known aspects of 
the nuclease function of SAN1. SAN1 has a ssDNA length requirement of greater than 25 
nucleotides because there is a portion of the C-terminus of SAN1 that interacts with the 
ssDNA and substrates shorter than 25 nucleotides are not readily able to interact with 
both regions of the protein. This would make ssDNA sequences shorter than 25 
nucleotides undesirable substrates. As a feature of a larger splayed arm or 5’ flap 
structure the ssDNA length requirement is less than 25 nucleotides because the C-
terminus interacts with the bottom strand of DNA present in the flap or splayed arm 
structure. This model also provides an explanation for the increased cleavage efficiency 
of the splayed arm structure over the 5’ flap structure. The C-terminus of SAN1 interacts 
with the bottom ssDNA portion of the splayed arm structure and thus is able to cleave the 
splayed arm substrate readily whereas in the 5’ flap structure the bottom strand of DNA 
is double stranded and thus provides a less favorable interaction with the C-terminus of 
SAN1 (Figure 15). This model of SAN1 nuclease activity on ssDNA sequences, as 
compared to other multi-strand DNA structures, is in line with the defining characteristic 
of FEN1 family members as nucleases that recognize structural components. From 
ssDNA/dsDNA junctions to flaps to lesions that produce bubbles and other structures in 
the DNA, the FEN1 family of nucleases recognizes and binds to structural components of 
potential substrates. SAN1 therefore represents a previously uncharacterized member of 
the FEN1 family that increases biological significance of the nucleases in the group by 
adding to the repertoire of substrates that family members act on.  
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Figure 15. Schematic of a model for SAN1 nuclease activity on DNA structures. 
SAN1 acts on ssDNA substrates by recognizing the free 5’ end of DNA and cleaving ~3 
or ~7 nts from the 5’ end, in a non-processive manner. SAN1 prefers splayed arm 
substrates over 5’ flap substrates because SAN1 is able to interact with the bottom strand 
of ssDNA in a splayed arm substrate whereas the bottom strand of DNA in a 5’ flap 
substrate is double stranded making it a less desirable substrate for the C-terminus of 
SAN1 to potentially interact with.  
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3.1 Abstract 
 
 
SAN1 is the first nuclease found to be involved in ICL repair since FAN1 was 
identified in 2010. Studies show SAN1 is required for colony survival of cells treated 
with ICL agents MMC or cisplatin but not for survival of cells treated with ionizing 
radiation which generates single-stranded DNA breaks and double-stranded DNA breaks. 
SAN1-/- HeLa cells and SAN1-/- mouse embryonic fibroblasts (MEFs) show similar levels 
of sensitization to ICL agents and in both systems expression of WT SAN1 but not D90A 
SAN1 is able to rescue resistance to ICLs. As a follow up to the initial colony survival 
assay (CSA) data we also show that SAN1-/- cells show increased chromosomal 
aberrations and radials as a result of MMC treatment, a phenotype similar to that seen in 
FA patients. Although SAN1-/- cells treated with MMC show a FA phenotype by 
cytogenetic analysis, additional studies have shown that SAN1 is not epistatic to 
FANCD2, and thus likely does not function in the FA pathway. Identification of 
Senataxin as a SAN1 interacting protein along with SAN1 being epistatic to SNM1a, a 
known nuclease involved in transcription-coupled ICL repair provide evidence for the 
involvement of SAN1 in a replication-independent ICL repair pathway. 
 
3.2 Introduction 
 
 
     DNA interstrand crosslinks (ICLs) are a toxic form of DNA damage that disrupts 
transcription and replication by covalently and irreversibly joining complementary DNA 
strands103. ICL agents all cause varying levels of distortion in the DNA helix upon 
binding to the DNA and thus represent a fairly diverse group of damaging agents60. 
Cisplatin causes highly distorting lesions while MMC causes less distortion in the DNA 
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helix104. Various ICL agents also cause different numbers of ICLs and intrastrand 
crosslinks105. Mono-ubiquitylation of the FANCI-FANCD2 (ID2) heterodimer leads to 
recruitment of multiple nucleases that control nucleolytic incision and ICL unhooking106, 
including the endonucleases XPF (FANCQ), which forms an XPF-ERCC1 heterodimer, 
and SLX1, with additional nucleases such as FAN1, SNM1A and MUS81 contributing 
independently of the FA pathway64,66,72. XPF-ERCC1, which is involved in nucleotide 
excision repair, is recruited to perform the unhooking incisions64,72, but under some 
circumstances it only performs the 3’ incision, and another nuclease would be responsible 
for the 5’ incision. The identity of this nuclease remains ambiguous but SLX1 is one 
candidate11. FAN1, a nuclease that interacts with FANCD2, can digest recessed 5’ DNA 
ends and cleave 4 nucleotides 3’ to an ICL56 but is not required for unhooking in Xenopus 
extracts and its function in ICL repair remains unclear59. Another nuclease, SNM1A, has 
no known function in incision, but may participate in repair by digesting past the ICL72. It 
remains unclear whether a single nuclease is responsible for the 5’ incision, or if several 
nucleases act redundantly to complete this process.   
 
     ICL repair can also be triggered by stalling of transcription complexes at lesions 
during other periods of the cell cycle, including G127. One consequence of transcriptional 
stalling is the formation of R-loops, which consist of a RNA-DNA hybrid plus the looped 
single-stranded coding strand of the DNA107. R-loops form naturally during transcription 
at promoters of genes with a high GC content and at termination regions of genes107. 
Persistent R-loops can impede replication and be processed into double stranded breaks 
(DSBs), leading to genomic instability. ICLs between RNA and DNA strands might also 
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occur at these structures, although to date there is no direct evidence for their existence. 
R-loops can be resolved by an endonuclease, RNase H, or by an RNA/DNA helicase, 
Senataxin (SETX), and if they persist can be aberrantly processed into DSBs by the NER 
endonucleases XPF and XPG108. Interestingly, R-loop resolution has recently been linked 
to the FA pathway107,109, and to BRCA1110, a protein essential for HR and resistance to 
ICLs.  
 
3.3 Results and Discussion 
 
 
 After identifying SAN1 to be a new and unique 5’ ssDNA exonuclease, I also wanted 
to understand if SAN1 acts as a nuclease in vivo and, if so, in what type of DNA repair 
pathway SAN1 could be functioning in. Data showed that when SAN1 is depleted in cells 
by shRNA and cells are treated with different DNA damaging agents (MMC, cisplatin, 
IR, MMS) SAN1 depleted cells are sensitized to only the ICL agents MMC and cisplatin 
(data not shown). IR causes single- and double-stranded breaks that are commonly 
repaired by HR or NHEJ pathways, while MMS is an alkylating agent that is repaired by 
BER.  
 
 I generated a SAN1 knockout cell line in HeLa cells using CRISPR/Cas9 genome 
editing technology to follow up on this result. To abolish nuclease activity of SAN1, two 
guide RNAs were used that would facilitate deletion of almost 400 base pairs from the 
nuclease domain of SAN1 (Figure 16a). Clones were screened by PCR, sequencing, and 
western blot to determine which clones were potential SAN1 knockouts and to validate 
that they were in fact not producing detectable levels of SAN1 (Figures 16a, b).  
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Alex Andrews – CSAs and generation of MEF cell line 
 
FIGURE 16. Loss of SAN1 leads to sensitization of cells to ICL agents (a) Schematic 
showing CRISPR-Cas9 strategy to create SAN1-/- HeLa cell lines. Two guide RNAs were 
used to delete a 362 bp region of exon 1 in the fam120b gene locus, which contains the 
conserved FEN1 family nuclease domain. (b) Immunoblot of HeLa WT parental cell line 
and CRISPR-Cas9 generated SAN1-/- cell lines showing loss of SAN1 expression (lanes 
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1-7). β-tubulin was used as a loading control. (c-e) SAN1-/- cells were transduced with 
lentiviral constructs expressing Strep2-FLAG tagged SAN1 WT or the D90A mutant to 
create stable rescue cell lines. Colony survival assays (CSAs) were then performed using 
HeLa WT, SAN1-/-, and WT or D90A rescue lines with MMC, Cisplatin, or ionizing 
radiation (N > 3). Statistical significance determined by two-way ANOVA comparing 
HeLa WT and SAN1-/- or SAN1-/- +WT and SAN1-/- +D90A. Error bars denote s.e.m. * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. (f) Immunoblot showing SAN1 
expression in HeLa WT, SAN1-/-, and SAN1 WT and D90A rescue lines. GAPDH was a 
loading control. (g-i) SAN1+/- mice were crossed to generate SAN1+/+ and -/- mouse 
embryonic fibroblasts (MEFs). The MEFs were immortalized using SV40 large T 
antigen, and the SAN1-/- MEFs were transduced with lentiviral constructs containing 
Strep2-FLAG-tagged human SAN1 WT or SAN1 D90A. These cell lines were then used 
for CSAs with MMC, Cisplatin, or ionizing radiation (N=3). (j) Immunoblot showing 
mouse SAN1 expression in SAN1 +/+ and -/- MEFs (left panel) and hSAN1WT and 
hSAN1D90A expression in SAN1-/- cells (right panel). GAPDH was used as a loading 
control. Statistical significance for CSAs was determined by two-way ANOVA test 
comparing SAN1+/+ and SAN1-/- or SAN1-/- + hSAN1WT and SAN1-/- + hSAN1D90A.  
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Stable cell lines expressing WT or D90A SAN1 were developed from the SAN1-/- HeLa 
cell line to determine if the nuclease function of SAN1 was required for protection 
against sensitivity to these DNA damaging agents (Figures 16c, d, e). By colony survival 
assay (CSA), SAN1-/- cells showed increased sensitivity compared to WT HeLa cells 
following treatment with MMC or cisplatin. While the SAN1-/- +WT cell line was able to 
rescue survival similar to HeLa WT levels, the SAN1-/- +D90A line is still sensitized to 
crosslinking agents similar to the SAN1-/- line alone. This result shows that SAN1 
nuclease activity is required for protection against ICL sensitivity (Figures 16c, d). Also 
in agreement with the initial CSAs, SAN1-/- cells are not sensitized to damage resulting 
from IR which produces single-stranded DNA breaks and double-stranded DNA breaks 
(Figure 16e). Together, these results point to SAN1 nuclease activity playing a role in 
ICL-specific repair before the HR step downstream of ICL unhooking. The repair of ICLs 
requires the coordination of several repair pathways including NER, TLS, and HR. 
Further, these data also show that the nuclease function of SAN1 must be important in 
ICL repair specifically and not in a downstream process of ICL repair like HR. Figure 16f 
is a western blot showing relative expression levels of WT HeLa cells, SAN1-/- HeLa 
cells, SAN1-/- +WT cells, and SAN1-/- +D90A cells. The expression levels of WT and 
D90A SAN1 relative to endogenous SAN1 were increased in the SAN1-/- + WT and 
SAN1-/- + D90A stable lines, although we do not predict that this increased expression 
confounds the initial result. Western blots of SAN1-/- HeLa, SAN1-/- + WT, and SAN1-
/- +D90A cell lines are shown in Figure 16j and Appendix I (Figure 23a, b).  
 
As an independent method to determine the role of SAN1 in the response to DNA  
 		 	 	63	
 
Tim Errington - panel B 
 
FIGURE 17. SAN1-/- cells proliferate normally and are not sensitized to 
Hydroxyurea or camptothecin. (a) Proliferation assay of WT HeLa cells and SAN1-/- 
HeLa cells generated by CRISPR/Cas9 technology. Cells were plated in triplicate on day 
0 and were trypsinized and counted each day for 4 days. Error bars represent SEM. (b) 
Cell cycle distribution of cells treated with SAN1 or control siRNA and vehicle or 
Cisplatin. Immunoblot (left panel) shows knockdown of SAN1 by siRNA. Ran was used 
as a loading control. Clonogenic survival assays of WT HeLa cells compared to SAN1-/- 
HeLa cells after treatment with (c) hydroxyurea, (d) camptothecin (e) etoposide. 
Statistical significance for CSAs was determined by two-way ANOVA test. Error bars 
denote s.e.m. * = p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001.  
the cells.   
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damage, we created a conditional KO mouse, and generated mouse embryonic fibroblasts 
(MEFs) through the Texas A&M Institute for Genomic Medicine, using EUCOMM ES 
cells targeting the fam120b gene (ES cell clone HEPD0652_5_G10). A fam120b/+ male 
was crossed to a FLPer/+ female to delete the lacz/neo markers, the FLPer transgene was 
then removed by crossing to a +/+ mouse, and the resulting floxed allele mice were 
crossed to produce homozygotes. These homozygous mice were then crossed with a 
Sox2-Cre mouse to obtain a global knockout of the allele. From these SAN1-/- mice, 
which were viable and fertile, we isolated primary embryonic fibroblasts. Because 
primary fibroblasts do not proliferate when plated as single cells, they were immortalized 
using the SV40 the large T antigen, and lines were created from SAN1-/- and SAN1+/- and 
WT+/+ littermates. These lines were then tested for sensitivity to DNA damaging agents. 
The homozygous knockout cells, SAN1-/- MEFs, showed significantly increased 
sensitivity to ICL agents as compared to WT cells (Figures 16g, h), and were not 
sensitive to IR (Figure 16i). Moreover, re-introduction of human SAN1-ssf (strep-strep-
FLAG tag) WT rescued survival but the D90A mutant did not (Figures 16g, h, i). Taken 
together, these data demonstrate that SAN1 nuclease activity is required for survival in 
response to ICL agents, but not to drugs that induce single- or double-stranded DNA 
breaks, suggests the finding that SAN1 plays a role in ICL repair but does not participate 
in HR or non-homologous end joining (NHEJ). Raw western blots of SAN1-/- MEFs, 
SAN1-/- + hWT MEFs, and SAN1-/- + hD90A MEFs cell lines are shown in Appendix I 
(Figure 23c). 
 
 In addition, SAN1-/- cells proliferate similarly to WT HeLa cells and SAN1  
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Alan D’Andrea Lab- Cytogenetic Analysis 
 
FIGURE 18. SAN-/- cells display increased levels of radial chromosomes in response 
to MMC. (a, b) Micrographs of metaphase spreads from untreated HeLa WT and SAN1-/- 
cells. (c, d) Micrographs of metaphase spreads of HeLa WT and SAN1 -/- cells following 
treatment with 0.03 mM MMC, showing large increase in radials or other chromosomal 
aberrations in SAN1-/- cells. Red arrows indicate radial chromosomes or aberrations. (e,f) 
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Quantification of aberrations/cell and percentage of radials/cell for HeLa WT and SAN1 -
/- cells treated with MMC. Metaphase spreads from 50 HeLa WT cells were analyzed (11 
radial forms, 11 cells with radials, 40 aberrations). Metaphase spreads from 25 SAN1-/- 
cells were analyzed (42 radial forms, 15 cells with radials, 121 aberrations). Data were 
analyzed in Prism GraphPad from contingency tables using Fisher’s exact-test (two-sided 
P value). 
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knockdown cells shown a normal cell cycle profile as compared to cells treated with 
control siRNA with and without cisplatin (Figures 17a, b). These results, along with the 
SAN1-/- HeLa CSA data and the SAN1-/- MEF CSA data, confirm that removal of SAN1 
from cells does not alter normal proliferation or cell cycle progression but does strongly 
sensitize cells to ICL agents MMC and cisplatin.  
 
 In addition to testing the DNA damaging agents MMC, cisplatin, and IR, we wanted to 
determine if SAN1 knockout cells showed sensitivity to any other replication-dependent 
DNA damaging agents. Using WT HeLa cells and SAN1-/- HeLa cells CSAs were 
performed with hydroxyurea, camptothecin, and etoposide. Hydroxyurea is a potent 
inhibitor of the enzyme ribonucleotide reductase that prevents replication by depleting 
the pool of dNTPs available at the replication fork for DNA synthesis. Camptothecin is a 
topoisomerase I poison that blocks disassociation of the topoisomerase I from DNA 
causing single-stranded DNA breaks. Etoposide, on the other hand is a topoisomerase II 
poison that blocks disassociation of the topoisomerase II from DNA, resulting in 
persistent DNA double-stranded breaks that can cause chromosomal aberrations or 
rearrangements. Each of these drugs causes significant replication stress. SAN1 deletion 
had little effect on sensitivity to hydroxyurea and camptothecin but did show a slight 
sensitivity to etoposide (Figures 17c, d, e). FA proteins are known to have roles in other 
pathways including replication fork protection and even cytokinesis11. Although we 
predict that SAN1 may have an additional function in an etoposide-related repair 
pathway, these results broadly confirm that SAN1 knockout cells show the most 
significant sensitivity to ICL-inducing agents including MMC and cisplatin. Additional  
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Alex Andrews – Figure 19 
 
FIGURE 19. SAN1 functions independently of the FA pathway and does not affect 
FA pathway activation. (a. b) CSAs of HeLa WT and SAN1 -/- cells treated with 
scrambled ctrl siRNA or FANCD2 siRNA, in response to Cisplatin and MMC (N=3). 
Statistical significance determined by two-way ANOVA. Error bars denote s.e.m. * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. (c) Immunoblot showing siRNA 
knockdown of FANCD2 in HeLa WT and SAN1-/- cells. 
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investigation is required to determine if SAN1 plays a minor role in another pathway. 
 
Because SAN1-/- cells show an increased sensitivity to crosslinking agents such as 
MMC and cisplatin in colony survival assays, it was critical to determine if the SAN1-/- 
HeLa line showed a similar phenotype to FA patients by cytogenetic analysis. The results 
from the cytogenetic analysis are shown in Figure 18. Untreated SAN1-/- cells show few 
chromosomal breaks or radials but treatment with 0.03 mM MMC significantly increased 
the number of breaks and radials relative to WT HeLa treated cells. As our SAN1-/- cell 
line showed a similar phenotype to FA patient cells (who display severe sensitivity to 
ICL-inducing agents) the results pointed to a role for SAN1 in FA-mediated ICL repair. 
This assay is the gold standard for diagnosing patients with FA. In the clinic, patient 
blood samples are taken and treated with ICL-inducing agents MMC, cisplatin, or 
diepoxybutane (DEB) before being scored for chromosomal breaks and radials. These 
breaks and radials result from the inability to repair ICLs, resulting in double-stranded 
DNA breaks and the aberrant activation of NHEJ pathway, which is highly error prone. 
Chromosomes can be mistakenly repaired to other chromosomes resulting in radial 
structures, or fragments can be lost entirely resulting in cell death. It is also important to 
note that in the assay with the parental WT HeLa cell line, WT HeLa cells showed 
minimal chromosomal breaks or aberrations without DNA damaging agents and 
significantly fewer breaks or radials when treated compared to the SAN1-/- HeLa line 
treated (Figures 18a-d). The SAN1-/- HeLa line treated with MMC showed five-fold 
greater aberrations per cell and three-fold greater cells with radials than treated WT HeLa  
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Alex Andrews – Panels B, C, D 
 
FIGURE 20. SAN1 interacts with Senataxin and interaction is required for ICL 
resistance. (a) Yeast two-hybrid (Y2H) screen and library information in addition to a 
schematic detailing mSETX prey fragments that interacted with mSAN1 in Y2H screen. 
The shared interaction domain of mSETX prey fragments shows that SAN1 interacts with 
SETX in a region of the N-terminus and not near the RNA/DNA helicase domain at the 
C-terminus. (b) Endogenous SAN1 was co-immunoprecipitated from HeLa WT and 
SAN1 -/- after treatment with 1 mM MMC. Top panel: immunoblot (IB) of Senataxin 
inputs (lanes 1-2) and Co-IP (lanes 3-4), bottom panel: IB of SAN1 inputs (2%) (lanes 1-
2), and Co-IP (lanes 3-4). (c-d) CSAs for HeLa WT, SAN1-/-, and SAN1-/- +SAN1ΔRep-
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ssf cells exposed to Cisplatin and MMC. Statistical significance determined by two-way 
ANOVA. 
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cells which represent very significant increases in response to these ICL agents (Figures 
18e, f).  
 
Next, epistasis experiments were used to determine whether SAN1 functions as a 
nuclease within the FA pathway, the canonical mechanism for ICL repair. FANCD2, a 
central component of the FA pathway was depleted in WT HeLa cells or in the SAN1-/- 
HeLa background. FANCD2 plays a critical role in the activation of the FA pathway, and 
acts upstream of proteins that function in the nucleolytic steps of ICL repair such as 
SLX1-SLX4, XPF-ERCC1, and FAN19,26,27. Treatment of WT HeLa cells with FANCD2 
siRNAs led to a sharp decrease in cell survival when cells were exposed to low doses of 
Cisplatin or MMC, as previously reported (Figures 19a-c)28. Strikingly, when FANCD2 
was depleted in SAN1-/- cells, a synergistic increase in the sensitivity of SAN1-/- cells to 
ICLs occurred. In these experiments, we observed only a small to negligible decrease in 
survival between HeLa WT and SAN1-/- cells at very low concentrations of Cisplatin and 
MMC. The synergistic increase in sensitivity after depletion of FANCD2 in SAN1-/- cells 
suggests that ICLs are predominantly processed by the FA pathway and that SAN1 might 
function in a secondary pathway if the FA pathway is overwhelmed by abundant ICLs. 
Collectively, our data argue that SAN1 is not epistatic to FANCD2, and functions 
independently of the FA pathway (Figures 19a-c).  
 
To probe the function of SAN1, we sought potential interacting proteins using a 
Hybrigenics genome-wide yeast two-hybrid (Y2H) screen. Full length murine SAN1 was 
used as bait, and was screened against a mouse adult brain library with a complexity of  
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Alex Andrews- Panels A, B 
 
FIGURE 21. SAN1-/- cells show increased R-loop formation with MMC treatment. 
(a) Quantification of nuclear R-loop intensity (N=3). HeLa WT and SAN1-/- cells were 
treated with vehicle or 1 mM MMC and labeled with a monoclonal antibody to detect 
RNA/DNA hybrids (S9.6), nucleolin, and Draq5. Statistical significance calculated using 
unpaired t-test (N=3 biological replicates, at least 60 cells per sample were analyzed). (b) 
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HeLa WT and SAN1-/- cells were treated with vehicle or 1 mM MMC and labeled with a 
monoclonal antibody to detect R-loops (S9.6), a polyclonal antibody against nucleolin, 
and Draq5 to label DNA. Intensity of nuclear R-loop staining was quantified from the 
nucleus following masking with the DRAQ5 channel, and subtraction from nucleolin 
regions. (c) Dot blot assay for quantification of RNA/DNA hybrids. (N=4) Statistical 
significance determined by unpaired t-test comparing each condition to HeLa treated. (d) 
Colony survival assay of HeLa WT, SAN1-/-, SAN1-/- +WT and SAN1-/- +D90A cell lines 
following exposure to UV. 
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~1x107, at 10-fold coverage. From 103 million analyzed reactions, 183 clones were 
processed, and 9 positive clones were in-frame and were present more than once (Figure 
20a, Appendix I - Figure 24). Amongst these high-confidence hits was Senataxin 
(SETX), a gene mutated in ataxia oculomotor apraxia type 2 (AOA2) and juvenile 
amyotrophic lateral sclerosis (ALS4)33,34. SETX has been shown to participate in several 
different DNA damage responses, and functions centrally as a RNA/DNA helicase in the 
resolution of R-loops35. A small region of this protein, mSETX (876-1103), N-terminal to 
the helicase domain, bound to SAN1 (Figure 20a). Based on the role of Senataxin 
(SETX) in various areas of the DNA damage response, we explored whether an 
interaction between SAN1 and SETX is important for SAN1 function. 
Immunoprecipitation of endogenous SAN1 co-precipitated a protein detected by an anti-
SETX antibody from HeLa WT cell nuclear extracts, but not from SAN1-/-cells (Figure 
20b). Moreover, unlike SAN1WT-ssf, SAN1ΔRep-ssf was unable to interact with full 
length SETX-Flag-GFP (data not shown) and was also still active as a nuclease (Figure 
14f). We next used this mutant to test if SAN1 binding to SETX is essential for ICL 
resistance. Strikingly, the SAN1ΔRep-ssf mutant was unable to rescue survival in SAN1-
/- cells treated with Cisplatin or MMC (Figures 20c, d).   
 
Finally, given the known role of SETX in resolving R-loops, we asked whether the 
loss of SAN1 might lead indirectly to R-loop accumulation, from a failure to repair and 
remove ICLs. To test this possibility, we performed immunofluorescence staining of 
HeLa WT and SAN1-/- cells using the S9.6 monoclonal antibody, which specifically 
detects RNA-DNA hybrids. Co-staining with nucleolin antibody was used to subtract the 
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constitutive presence of RNA-DNA hybrids in the nucleoli. No significant difference in 
R-loops was found between untreated and MMC treated HeLa WT cells. However, the 
abundance of R-loops in SAN1-/- cells after MMC treatment was significantly increased 
(Figures 21a, b). To provide an independent assessment of R-loop formation, a dot blot 
assay was used in which isolated genomic DNA is probed for RNA/DNA hybrids with 
the S9.6 antibody, and normalized to total ssDNA (Figure 21c). Treatment of cells with 
MMC caused a significant increase in R-loops in SAN1-/- cells compared to WT cells. 
Moreover, the re-expression of WT SAN1, but not of the nuclease-defective D90A 
mutant, blocked any increase in R-loop formation in response to MMC (Figure 21c). I did 
not observe a similar increase between SAN1-/- cells compared to HeLa WT cells in 
untreated conditions as in the S9.6 staining in Figures 21a, b; however this might reflect 
differences in assay sensitivity or dynamic range. Representative slot blots shown in 
Appendix I (Figure 23d).  
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4.1 Discussion 
 
Every day, cells in the body are exposed to many DNA damaging agents. DNA 
damaging agents create tens of thousands of DNA lesions that when left unrepaired result 
in genomic instability and ultimately diseases such as premature aging and cancer111. To 
repair these lesions in a timely manner and to prevent genomic stress, an extensive 
network of repair pathways have evolved, collectively called the DNA damage response4. 
Although a vast array of protein components of many of the DNA damage response 
pathways have been identified, there remains a lack of understanding of how the network 
of DDR pathways interact to repair certain types of lesions throughout the cell cycle. One 
particularly complicated lesion to repair is the interstrand crosslink (ICL). ICLs are 
extremely cytotoxic, as they covalently link the strands of DNA resulting in a block of 
normal cellular processes such as replication and transcription56. Repair of ICLs also 
requires the interaction of several different repair pathways including nucleotide excision 
repair (NER), homologous recombination (HR), and translesion synthesis (TLS)71. 
Mammals have also developed an additional pathway to repair ICLs called the FA 
pathway which is critical in replication-dependent ICL repair63. The FA pathway is an 
extensive network of over 20 proteins, deficiency in any one of which leads to FA 
development77. The FA pathway and replication-dependent ICL repair are only active in 
S and G2 phases of the cell cycle, leaving cells susceptible to ICL damage outside of 
replication that must also be repaired. There is significantly less known about replication-
independent ICL repair, thus representing an area of the field requiring additional 
research focus to further understand. This study characterizes a new nuclease component 
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of replication-independent ICL repair that acts on various ssDNA structures and is 
required for protection against ICL sensitivity.  
 
Senataxin-associated nuclease 1 has been shown to display a unique nuclease activity 
on 5’ ssDNA. SAN1 shares sequence homology with another known nuclease family, the 
FEN1 family of structure specific nucleases that function in various aspects of DNA 
replication and repair. Importantly, SAN1 has the same N and I regions of the nuclease 
domain that represent the regions of DNA binding and Mg2+ binding within the active 
site. SAN1 requires a free 5’ end of DNA for binding proving it to be a true exonuclease, 
and prefers Mg2+ as a metal cofactor for nuclease reactions, similar to other members of 
the family. The FEN1 family represents a group of nucleases with a wide range of 
substrate preferences. FEN1, EXO1, GEN1, and XPG all cleave very different substrates 
but have homologous nuclease domains providing an interesting look into how these 
proteins employ different structural motifs to probe the nucleic acid environment 
surrounding potential substrates78. These structural regions, or pockets, on the enzymes 
increase substrate recognition and binding affinity. Studies examining the structures of 
FEN1 and EXO1 bound to DNA substrates have also identified other important features 
of the FEN1 family, including a K+-binding site, a hydrophobic wedge, and a helical 
gateway formed by alpha helices83,87,88.  
 
In addition to SAN1 possessing the same catalytic residues and structural components 
as other members of the FEN1 family, SAN1 also has a unique C-terminus and internal 
repeat region. The C-terminus interacts with the N-terminus and the C-terminus is 
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required for nuclease activity. As the regulation of nucleases is critical in preserving 
genomic integrity, the C-terminus of SAN1 could function as a regulator of SAN1 
nuclease activity, thus preventing aberrant cleavage.  SAN1 also possesses a unique 
repeat region, which we hypothesize allows for flexibility for the interaction between the 
N-termini and C-termini to stimulate substrate binding or nuclease function. Interestingly, 
although this repeat motif has not been found in other proteins, the SAN1 repeat motif 
has been shown to possess different numbers of repeats across species that have SAN1. 
For example, humans typically have twelve repeat motifs and mice typically have six 
repeat motifs. The internal repeat region is also not required for nuclease activity. Future 
studies examining if the internal repeat region functions as a flexible linker between the 
N- and C-terminal regions are necessary to more fully understand the contributions of 
various domains of SAN1. One possible avenue would be to design an alternative flexible 
linker and create a fusion protein of the N-terminus of SAN1 and the C-terminus of 
SAN1 connected by this alternative linker. After expressing and purifying this mutant 
protein, nuclease activity could be examined. If the nuclease domain and C-terminus are 
still able to interact through the alternative flexible linker then the mutant protein should 
show nuclease activity on a single-stranded DNA substrate. In addition to possibly 
functioning as a flexible linker, we know from the mapping experiments that the internal 
repeat region is the site of SAN1 interaction with Senataxin, an RNA/DNA helicase. We 
have also shown that SAN1∆Repeats expressed in SAN1-/- cells does not restore 
protection against ICL sensitivity, providing evidence that the interaction with Senataxin 
is potentially important in the relationship between SAN1 nuclease activity and ICL 
repair. 
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FEN1 family members are thought to recognize substrates using either a “threading” 
or “tracking” mechanism. In the threading model, the nuclease recognizes the free 5’ end 
of DNA and threads down to the ssDNA/dsDNA junction. For example, EXO1 cleaves 
flap structures via this threading mechanism, albeit inefficiently. EXO1 is able to 
recognize the free 5’ flap and thread down to the ssDNA/dsDNA junction allowing for 
cleavage 1 nucleotide in from the ssDNA/dsDNA junction78,86. Conversely, in the 
tracking model the nuclease recognizes the ssDNA/dsDNA junction alone and is able to 
bind and cleave without recognizing the ssDNA end alone. FEN1, GEN1 and XPG can 
all recognize substrates using the tracking mechanism, recognizing the ssDNA/dsDNA 
junction and acting to resolve those structures (in a flap, Holliday Junction, or bubble) 
then proceeding with DNA replication or repair80. Here, I provide evidence based on the 
requirement of a free 5’ end of DNA that SAN1 utilizes a threading mechanism to bind 
substrate and initiate cleavage. In addition to threading the ssDNA flap, the requirement 
of the C-terminus for nuclease activity and the increased cleavage capability for a splayed 
arm structure provide evidence for a model in which the C-terminus interacts with the 
bottom strand of ssDNA to increase nuclease activity.  
 
SAN1 shows increased cleavage capability on splayed arm structures over ssDNA or 
5’ flap structures. These data support a model in which increased cleavage of splayed arm 
structures together with the binding requirement of the C-terminus for nuclease activity 
could account for increased substrate affinity or selection similar to other FEN1 family 
members. The interaction of the C-terminal region with the N-terminal region may 
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stimulate substrate binding or cleavage activity on splayed substrates more efficiently 
than on ssDNA substrates (that have a size requirement) or 5’ flap structures (that have 
dsDNA on the bottom strand). Additional experimentation is required to understand the 
detailed mechanism of how, beyond the requirement of a free 5’ end of DNA, SAN1 
recognizes and binds to various substrates. Studies using EMSA assays to probe and 
analyze the binding capabilities of SAN1 D90A to various substrates would shed light on 
some of these possible mechanisms. Increasing concentrations of SAN1 D90A should 
lead to increased binding of substrates and a quantitative analysis of binding would 
identify substrates that are more efficiently bound by SAN1 D90A at various 
concentrations of enzyme.  
 
In nuclease assays, SAN1 cleaves splayed arm structures the most efficiently, 
supporting a model in which SAN1 acts similarly to other FEN1 family members and 
recognizes or interacts with additional regions of the DNA structure for increased 
substrate specificity. The preference for cleaving the 5’ flap of a splayed arm structure 
indicates that SAN1 acts on an intermediate 5’ ssDNA flap that is part of a splayed arm 
structure after resolution of an R-loop structure and the action of another endonuclease 
such as XPF. SAN1 may then act on an intermediate structure after the initial cleavage 
event, processing the substrate for further repair. This would open the possibility for a 
nuclease like SNM1a to act downstream of SAN1 to digest past the ICL allowing for 
unhooking and subsequent repair steps. Persistent R-loops can result in double-stranded 
break formation and other genomic stress109,112. SAN1-/- cells have increased R-loop 
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formation following MMC treatment and the inability to repair ICLs in the absence of 
SAN1 could account for the observed persistent R-loops.  
 
In addition to understanding the structure and function of SAN1, I also investigated if, 
and how, SAN1 acted as a nuclease in vivo. Disruption of the gene for the SAN1 
nuclease, Fam120b, had no effect on cell cycle, but specifically increased sensitivity to 
cross-linking agents, and resulted in DNA damage and radial chromosome formation in 
the presence of Mitomycin C (MMC). Global analysis of gene expression by RNA-
Sequencing failed to detect any significant differences either in expression levels or 
splice variants between MEFs from WT and Fam120b deleted mice, indicating that this 
protein does not significantly impact gene expression. Moreover, Fam120b knockout 
mice are viable and fertile.  
 
SAN1 is not epistatic with components of the FA pathway, including FancD2 and 
XPF. However, the interaction with Senataxin is required for SAN1 function. SAN1 
cooperates with SETX in an FA-independent repair process to protect cells from ICLs. 
Interestingly, the nuclease activity of SAN1 is the most similar to FAN1, a FANCD2 
interacting nuclease that was identified in 201065,67. Upon its discovery and connection to 
FANCD2 and the FA pathway, FAN1 was predicted to be the definitive 5’ nuclease to act 
in the unhooking step of ICL repair. Although FAN1 is able to unhook the ICL, it is not 
required for ICL resolution and thus XPF is the only nuclease that has been shown to be 
both required and sufficient for ICL unhooking. Patients with FAN1 mutations do not 
have FA but instead have a unique kidney disease called karyomegalic interstitial 
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nephritis, a disease that is entirely separate from FA. These observations led to a search 
for the true in vivo substrate of FAN1 to provide an understanding of the unique nuclease 
activity of SAN1 in the context of the landscape of ICL repair pathways. SAN1 is able to 
digest small fragments of DNA and does not appear to be processive, supporting a model 
in which SAN1 acts after an initial cleavage event by an endonuclease. As it is still 
unclear if and how each nuclease specifically functions in ICL repair, there remains the 
possibility that SAN1 has redundant function to other known nucleases including 
SNM1A or FAN1. Colony survival assay evidence shows that SAN1 does not appear to 
be acting epistatically to FAN1 but this does not rule out the possibility that these 
nucleases could perform similar functions in different pathways. This lack of epistasis 
also provides an explanation for why there would be the need for an additional nuclease 
in ICL repair. We do not yet know the exact step in ICL repair during which SAN1 
functions. A remaining question is whether SAN1 acts in coordination with protein 
cofactors other than Senataxin that have not yet been identified.  
 
Although I have shown that SAN1 does not appear to function in the FA pathway and 
we believe SAN1 functions in a transcription-coupled ICL repair pathway, there are still 
many areas of TC-ICL repair that are not clear.  The fact that SAN1 was not previously 
identified as a nuclease involved in ICL repair is likely due to its lack of involvement in 
the FA pathway, and accordingly, it would not have been identified in a FA pathway-
related screen. It is now clear that Senataxin, a SAN1 interacting protein, acts with 
BRCA1 to prevent the accumulation of R-loops in ICL repair. The connection between 
R-loop formation, and ICL repair, though, remains poorly understood110. SAN1 -/- cells 
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are sensitive to crosslinking agents and thus we predict that R-loops form as a result of 
stalling of the transcription complex at an ICL. An interesting way to test the relationship 
between ICL formation and R-loop generation would be to stimulate R-loop formation on 
a plasmid with a single site specific ICL and observe which factors are required for 
resolution of the lesion by immunodepletion. Several studies have been published using 
plasmids with single site-specific ICLs in a replication-dependent repair context; 
development of a similar system in a replication-independent repair context would shed 
light on the molecular mechanisms of repair59,60.  The R-loop must be resolved by a 
resolvase enzyme, such as Senataxin, that recruits SAN1 to the site of the ICL, allowing 
for SAN1 to act on an intermediate splayed arm structure after resolution of the R-loop 
and before the action of a nuclease such as SNM1a that can unhook crosslinks. 
Preliminary data shows that SAN1 appears to act epistatically to SNM1a, as there was no 
significant decrease in cell survival in a SAN1-/- SNM1a knockdown cell line treated with 
MMC (data not shown).  
 
Regulation of nucleases in ICL repair is critical for maintaining genomic integrity, and 
identifying different modes of SAN1 regulation would provide a stronger understanding 
of the TCR pathway. FA pathway nucleases are regulated by ubiquitylation of the 
FANCD2-FANCI complex and recruitment of the critical scaffolding protein SLX4. 
Although SLX4 does not have nuclease activity it is absolutely essential for FA pathway-
dependent ICL repair and acts as a recruitment factor and docking location for the ICL 
repair nucleases, XPF/ERCC1, SLX1, and MUS81/EME1.  
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Taken together, this work shows that SAN1 binding to the RNA/DNA helicase SETX 
is required for SAN1 to function in the response to ICLs. SAN1 and SETX likely 
cooperate in the same pathway, as depletion of SETX is epistatic with loss of SAN1. 
Consistent with this model, loss of SAN1 leads to an increase in R-loops following 
treatment with MMC, likely as a result of the inability of SAN1 to participate in a step of 
ICL repair. Collectively these studies support the existence of repair pathway in which 
SAN1 acts independently of the FA pathway to protect cells from ICLs. SAN1 might act 
in a backup pathway that is required when the FA pathway is overwhelmed. It is tempting 
to speculate that SAN1 acts with SETX at ICL sites where transcription complex stalling 
has occurred, and that the subsequent formation of R-loops recruits SETX, which in turn 
recruits SAN1. The formation of a ssDNA break near an RNA:DNA hybrid could lead to 
a 5’ splayed arm-like substrate after resolution of the R-loop by SETX. This would allow 
for digestion of the ssDNA flap adjacent to an ICL by SAN1, possibly providing a better 
substrate for the 5’ exonuclease SNM1A, which might unhook the lesion by digesting 
past the crosslink (Figure 22). Although further experimentation is required to understand 
the exact mechanism of SAN1 function in ICL repair, this study represents a significant 
advance in the understanding of a previously uncharacterized FEN1 family member and 
provides evidence for a new member of a replication-independent ICL repair pathway.  
 
4.2 Future Directions 
 
One of the main remaining questions regarding the function of SAN1 is in which step 
of ICL repair and on which ICL repair intermediates it is acting. The evidence that SAN1 
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acts epistatically of SNM1a provides support that SAN1 may be cleaving a precursor 
substrate that then is acted on by SNM1a. This could be tested by examining the nuclease 
activity of each protein separately followed by examining the nuclease activity of the 
combination of SAN1 and SNM1a in a nuclease assay on an ICL substrate. If SAN1 is 
able to act on a splayed arm structure with an ICL generating a substrate that SNM1a 
could then digest the ICL would be unhooked. However, we have not yet tested that 
experimentally.  
 
In addition to determining in which step of ICL repair SAN1 is acting, it would also be 
interesting to understand the preference of a splayed arm substrate. I developed several 
new oligonucleotides with several different lengths of 3’ ssDNA regions hypothesizing 
that if SAN1 is able to interact with a longer 3’ ssDNA region the 5’ strand will be more 
efficiently cut by the nuclease domain. Because I observed that SAN1 is able to cleave 
ssDNA, splayed arm, and 5’ flap structures but the splayed arm structures are cleaved the 
most efficiently, I posit that SAN1 would show increased activity against the substrate if 
the 3’ ssDNA region of the splayed arm is longer and thus provided a longer region for 
SAN1 to interact with. Understanding how SAN1 recognizes substrates beyond just 
requiring a free 5’ end of DNA would significantly advance our understanding of how the 
protein functions in vivo.  
 
Another important next step in the study of SAN1 will be to understand the regulation 
of the nuclease. FA pathway nucleases are regulated by activation of the FA pathway 
through phosphorylation and ubiquitylation along with recruitment to ICL sites through 
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SLX4113. SLX4 is a critical scaffolding protein that does not have nuclease activity but is 
required in the FA pathway to recruit the toolkit of nucleases required for unhooking the 
lesion64. SLX4 is recruited to the site of the ICL by monoubiquitylated FANCD2-
FANCI63. Identifying additional proteins with which SAN1 interacts or that regulate 
SAN1 will provide a deeper understanding of replication-independent ICL repair. As a 
critical SAN1 interacting protein, Senataxin binding to SAN1 is important for the ability 
of SAN1 to function in ICL repair. Many nucleases in DDR pathways require or are 
stimulated by the action of helicases45. One particularly interesting interaction is between 
the helicase BLM and the FEN1 family nuclease EXO1. BLM stimulates EXO1 nuclease 
activity on DNA substrates during HR45,95. It will be important to further characterize the 
interaction between the Senataxin helicase and SAN1 nuclease activity, and in particular, 
to understand if Senataxin is able to stimulate nuclease activity on substrates.  
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FIGURE 22. Speculative model for SAN1 function with SETX in processing of 
ICLs. Collision of transcription complexes with an ICL results in the formation of R-
loops. The helicase SETX is recruited to the RNA/DNA hybrid and unwinds it. SETX 
also recruits the SAN1 nuclease. If an incision is generated in the ssDNA loop, perhaps 
by XPF, SAN1 can digest the free 5’ end back to the ICL, where other nucleases 
participate in unhooking of the lesion.
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Alex Andrews – Figures B, C 
 
Figure 23. Raw blot data from Figures 16, 17, 21. (a) SAN1-/- HeLa cell clones 
generated using CRISPR/CAS9 and loading controls as shown in Figures 16, 17. (b) 
SAN1WT and SAN1D90A rescue lines and loading control as shown in Figure 16. 17. 
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(c) SAN1+/+ and SAN1-/- MEFs raw western blots from Figure 16. Middle right panels: 
MEF rescue cell line raw western blots and loading control from Figure 16. (d) 
Representative slot blot images (ssDNA blot and S9.6 blot) for HeLa, SAN1-/-, SAN1-/- 
+WT, SAN1-/- +D90A cells treated with or without MMC from Figure 21. 
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mSAN1	Yeast	Two-Hybrid	-	Hybrigenics	
Gene	Name Gene	ID	(NCBI) Global	PBS Start Stop Frame Sense %	Id	5p/3p
Mus	musculus	-	Clpb 20480 B 231 1005 IF Sense 99.1	/	97.4
Mus	musculus	-	Clpb 20480 B 258 924 IF Sense 100.0	/	99.7
Mus	musculus	-	Clpb 20480 B 282 1014 IF Sense 99.5	/	99.7
Mus	musculus	-	Hipk3 15259 B 1995 3068 IF Sense 99.3	/	99.6
Mus	musculus	-	Hipk3 15259 B 2151 3147 IF Sense 99.4	/	99.0
Mus	musculus	-	Hipk3 15259 B 2331 3159 IF Sense 98.3	/	99.6
Mus	musculus	-	Hipk3 15259 B 2373 3385 IF Sense 98.6	/	99.7
Mus	musculus	-	Lonrf1 244421 B 1125 2202 IF Sense 98.5	/	99.5
Mus	musculus	-	Lonrf1 244421 B 1443 2214 IF Sense 98.7	/	98.5
Mus	musculus	-	Lonrf1 244421 B 1443 2214 IF Sense 99.5	/	99.3
Mus	musculus	-	Lonrf1 244421 B 1443 2214 IF Sense 99.3	/	99.4
Mus	musculus	-	Pias2 17344 A 627 1792 IF Sense 99.2	/	99.3
Mus	musculus	-	Pias2 17344 A 1002 1747 IF Sense 99.9	/	99.8
Mus	musculus	-	Pias2 17344 A 1245 1746 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1248 1755 IF Sense 99.4	/	99.4
Mus	musculus	-	Pias2 17344 A 1251 1846 IF Sense 92.5	/	90.3
Mus	musculus	-	Pias2 17344 A 1251 2235 IF Sense 98.2	/	92.2
Mus	musculus	-	Pias2 17344 A 1257 1680 IF Sense 100.0	/	100.0
Mus	musculus	-	Pias2 17344 A 1290 1871 IF Sense 85.7	/	85.7
Mus	musculus	-	Pias2 17344 A 1290 1871 IF Sense 85.7	/	85.7
Mus	musculus	-	Pias2 17344 A 1332 1755 IF Sense 100.0	/	100.0
Mus	musculus	-	Pias2 17344 A 1332 1755 IF Sense 100.0	/	100.0
Mus	musculus	-	Pias2 17344 A 1332 1755 IF Sense 100.0	/	100.0
Mus	musculus	-	Rnf111 93836 B 861 1560 IF Sense 99.9	/	99.6
Mus	musculus	-	Rnf111 93836 B 861 1560 IF Sense 99.9	/	100.0
Mus	musculus	-	Rnf111 93836 B 954 1548 IF Sense 100.0	/	99.8
Mus	musculus	-	Setx 269254 B 1908 3369 IF Sense 99.6	/	99.9
Mus	musculus	-	Setx 269254 B 1908 3369 IF Sense 98.1	/	98.5
Mus	musculus	-	Setx 269254 B 2520 3432 IF Sense 99.9	/	99.9
Mus	musculus	-	Setx 269254 B 2625 3310 IF Sense 99.6	/	99.6
Mus	musculus	-	Smek1 68734 A -52 947 IF Sense 99.2	/	99.1
Mus	musculus	-	Smek1 68734 A -40 1133 IF Sense 99.6	/	98.7
Mus	musculus	-	Smek1 68734 A -40 1133 IF Sense 98.6	/	99.9
Mus	musculus	-	Smek1 68734 A 330 948 IF Sense 100.0	/	99.7
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Figure 24. Genome-wide yeast two-hybrid results from Hybrigenics. Full-length 
murine SAN1 was used as bait and was screened against a mouse adult brain library with 
a complexity of ~1x107, at 10-fold coverage. From 103 million analyzed reactions, 183 
clones were processed, and 9 positive clones were in-frame and were present more than 
once. 
Mus	musculus	-	Smek1 68734 A 375 1062 IF Sense 99.9	/	99.0
Mus	musculus	-	Smek1 68734 A 375 1062 IF Sense 100.0	/	99.0
Mus	musculus	-	Zfp142 77264 B 855 1518 IF Sense 99.4	/	99.5
Mus	musculus	-	Zfp142 77264 B 1026 1889 IF Sense 99.0	/	97.7
Mus	musculus	-	Zfp142 77264 B 1128 1954 IF Sense 99.0	/	99.9
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 2013 IF Sense 99.7	/	100.0
Mus	musculus	-	Zfp142 77264 B 1155 1512 IF Sense 100.0	/	100.0
Mus	musculus	-	Zmym2 76007 A 951 1956 IF Sense 99.7	/	99.8
Mus	musculus	-	Zmym2 76007 A 951 1956 IF Sense 99.9	/	99.9
Mus	musculus	-	Zmym2 76007 A 1056 2202 IF Sense 99.1	/	99.9
Mus	musculus	-	Zmym2 76007 A 1056 2202 IF Sense 97.9	/	99.3
Mus	musculus	-	Zmym2 76007 A 1086 2307 IF Sense 95.9	/	98.2
Summary	of	PBS	categories
A	:	Very	high	confidence	in	the	interaction
B	:	High	confidence	in	the	interaction
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X1 5'-TGGGTCAACGTGGGCAAAGATGTCCTAGCAATGTAATCGTCTATGACGTT-3' ssDNA 50	nt
X4 5'-AACGTCATAGACGATTACATTGCTAGGACATCTTTGCCCACGTTGACCCA-3' ssDNA 50	nt
a3 5'-CCTCGATCCTACCAACCAGATGACGCGCTGCTACGTGCTACCGGAAGTCG-3' Splayed arm, 3' flap, 5' flap, replication fork 50	nt
b 5'-CGACTTCCGGTAGCACGTAGCAGCGGCTCGCCACGAACTGCACTCTAGGC-3' Splayed arm, 3' flap, 5' flap, replication fork 50	nt
c 5'-GCCTAGAGTGCAGTTCGTGGCGAGC-3' Splayed arm, 3' flap, 5' flap, replication fork 25	nt
d3 5'-CGTCATCTGGTTGGTAGGATCGAGG-3' Splayed arm, 3' flap, 5' flap, replication fork 25	nt
X3 5'-TGGGTCAACGTGGGCAAAGATGTCC-3' ssDNA, first 25 nt of X1 25	nt
N1 5'-TGGGTCAACGTGGGCAAAGA-3' Nicked 20	nt
N2 5'-ATGTAATCGTCTATGACGTT-3' Nicked 20	nt
N3 5'-AACGTCATAGACGATTACATTCTTTGCCCACGTTGACCCA-3' Nicked 40	nt
G1 5'-TGGGTCAACGTGGGCAAAG-3' Gapped 19	nt
G2 5'-ATGTAATCGTCTATGACGTT-3' Gapped 20	nt
G3 5'-AACGTCATAGACGATTACATTCTTTGCCCACGTTGACCCA-3' Gapped 40	nt
X4 Biotin 5' 5'-Biotin-AACGTCATAGACGATTACATTGCTAGGACATCTTTGCCCACGTTGACCCA-3' X4 - 5' Biotin 50	nt
X1A 5'-TGGGTCAACGTGGGCAAAGATTTTTTTTTTTTTTTTTTTTTGTCCTAGCAATGTAATCTG-3' Variation of X1 - 1st 20 nt of X1, 20 internal Ts, middle 20 nt of X1 60	nt
X1B 5'-TTTTTTTTTTTTTTTTTTTTTGGGTCAACGTGGGCAAAGATTTTTTTTTTTTTTTTTTTT-3' Variation of X1 - 20 Ts, 1st 20 nt of X1, 20 Ts 60	nt
S3 5'-TGGGTCAACG-3' Ladder - 1st 10 nt from X1 oligo 10	nt
S4 5'-TGGGTCAACGTGGGC-3' Ladder - 1st 15 nt from X1 oligo 15	nt
S5 5'-TGGGTCAACGTGGGCAAAGA-3' Ladder - 1st 20 nt from X1 oligo 20	nt
S6 5'-TGGGTCAACGTGGGCAAAGATGTCC-3' Ladder - 1st 25 nt from X1 oligo 25	nt
S7 5'-TGGGTCAACGTGGGCAAAGATGTCCTAGCA-3' Ladder - 1st 30 nt from X1 oligo 30	nt
X0-1 5'-ACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC-3' Holliday Junction 60	nt
X0-2 5'-GGGTGAACCTGCAGGTGGGCAAAGATGTCCATCTGTTGTAATCGTCAAGCTTTATGCCGT-3' Holliday Junction 60	nt
X0-3 5'-ACGGCATAAAGCTTGACGATTACAACAGATCATGGAGCTGTCTAGAGGATCCGACTATCG-3' Holliday Junction 60	nt
X0-4 5'-CGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAGGCACTGGTAGAATTCGGCAGCGT-3' Holliday Junction 60	nt
Table	1.	Oligos	used	in	nuclease	assays
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1. Plasmids and siRNA 
 
-Human SAN1 cDNA (FLJ56631) was purchased from the NBRC, Japan, and 
cloned into the pRK7 expression vector with a C-terminal FLAG tag. SAN1 
(D90A) and SAN1 rescue constructs were made by QuikChange site-directed 
mutagenesis (Agilent Technologies). Partial mouse SAN1 open reading frames 
were obtained from GE Healthcare Dharmacon MGC cDNAs library and 
cloned into pASK-IBA3Plus to express full length SAN1-Strep-tag II. The 
D90A mutation was introduced using Stratagene QuikChange. pICE-RNaseHI-
WT-NLS-mCherry was a gift from Patrick Calsou (Addgene plasmid # 60365). 
For RNAi knockdown experiments SMARTpool siGENOME (Thermo Fisher 
and Dharmacon) siRNAs were used for SETX (M-021420-01-0005) and 
FAM120B (M-014898-00-0005). Cells were transfected, split 24 h later, and 
transfected again, with specific siRNA pools or a scrambled control (D-
001810-01-05) using RNAiMAX (Invitrogen) and Opti-MEM media (Thermo 
Fisher) according to manufacturer’s instructions. Colony survival assays were 
performed and lysates made 36 h after the second round of siRNA transfection. 
Knockdown was determined by western blotting using FANCD2 (1:500, Novus 
Biologicals NB100-182), SETX (1:1000, Novus Biologicals NB100-57542), 
SNM1a (1:1000, Bethyl Labs A303-747A-M), XPF (1:1000, Bethyl 
Laboratories A301-315A), FAN1 (1:1000, non-commercial), FAM120b 
(1:1000, Abcam ab106455). 
 
2. Production of hSAN1 from mammalian cells 
 
-pKSAN1WT-FLAG or pKSAN1D90A-FLAG constructs were transfected into 
293T cells. At 24 hrs post-transfection cells were washed once with 1× PBS 
followed by addition of Lysis Buffer (25 mM HEPES pH 7.4, 10% glycerol, 
1 mM EDTA, 1 mM DTT, 20 nM calyculin A (Sigma) and protease inhibitors 
(Roche)) and incubation on ice for 5 min. Samples were snap frozen in liquid 
nitrogen and subsequently thawed at 37 °C three times. NaCl was added to 
300 mM. Lysates were then centrifuged at 16,100×gfor 20 min at 4 °C and the 
supernatant was added to an equal amount of Lysis Buffer plus 0.2% NP-40 
and then centrifuged at 16,000×g for 5 min at 4 °C. Lysates were added to 
washed mouse anti-FLAG M2 agarose (Sigma) for 1 h at 4 °C. Samples were 
washed 2× with Wash Buffer (Lysis Buffer plus 0.1% NP-40 and 150 mM 
NaCl) for 15 min per wash at 4 °C. Samples were then washed 2× with Elution 
Buffer (62.5 mM HEPES pH 7.4, 62.5 mM KCl, 5% glycerol, 1 mM DTT, 50 
µg/mL BSA) for 15 min per wash at 4 °C, and SAN1 protein was eluted from 
beads with Elution Buffer + 150 ng/µL FLAG peptide (20 µL/10 cm, 
60 µL/15 cm) by shaking (600 rpm) at 4 °C for 30 min. Protein concentration 
was estimated by SDS-PAGE followed by Coomassie brilliant blue staining in 
parallel with known amounts of BSA. 
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3. 32P Labeling and oligonucleotide annealing 
 
-Defined oligonucleotide structures (ssDNA, dsDNA, nicked and gapped 
structures, replication fork, splayed arm structure, 5’ and 3’ flap structures) 
were 5’ -labeled with 5 pmol γ-[32P] ATP using T4 polynucleotide kinase 
(NEB) or 3’ -labeled with 5 pmol α-[32P] CordycepinTP using DNA terminal 
transferase (20 U) in 1× TdT buffer, supplemented with 2.5 mM CoCl2 in a 
10 µL reaction at 37 °C, according to standard methods (NEB). 
Oligonucleotides were annealed in 6× annealing buffer (0.9 M NaCl, 90 mM 
sodium citrate) by slow cooling from 95 °C and purified from 12% native 
PAGE gel by the crush and soak method. Oligonucleotide sequences are given 
in Appendix II. 
4. Nuclease assay standard reaction conditions 
-All reactions were carried out in nuclease buffer (62.5 mM HEPES pH 
7.4, 62.5 mM KCl, 5 % Glycerol, 1 µM DTT, 50 μg/mL BSA). Five 
micromolar of substrate was added to 4 µL of protein (27.5 nmol) or 
water and after the addition of Start Buffer (6 mM MgCl2, 2 mM β-ME, 
0.05 µg/µL BSA) reactions were incubated at 37 °C for 2 h (unless 
otherwise noted). Reactions were stopped using 2.5 µL of 5 × Stop Buffer 
(15 mM EDTA, formamide, 0.005% Bromophenol blue, 0.005% Xylene 
cyanol, 5% glycerol) followed by boiling the samples for 3 min. Unless 
otherwise stated DNA substrate sequences for individual experiments are 
shown schematically in each figure and listed in Appendix II. Reactions 
were analyzed on 12% denaturing PAGE gel (1× TBE, 7 M urea, 12% 
19:1 acrylamide/bis-acrylamide 19:1). 
 
5. RNA/DNA hybrid slot-blot assay 
 
-Hybrids were detected as described by Sollier et al (2014). Total nucleic acids 
were extracted from cells with the Qiagen DNeasy kit. DNA (1 µg) was spotted in 
duplicate wells onto positively-charged nylon membrane using a slot-blot 
apparatus, cross linked by UV treatment, and one well was probed with the S9.6 
antibody (1:1000, Kerafast, 1:200 ENH001). The DNA in the duplicate well was 
denatured for 10 min in 0.5N NaOH, 1.5M NaCl, then neutralized for 10 min in 1M 
NaCl, 0.5 M Tris-HCl (pH 7.0) and probed with an antibody against ssDNA 
(1:10000, Millipore MAB3034). Spots were detected with an anti-HRP secondary 
anti-mouse antibody, and imaged and quantified with an Amersham Imager 600. 
 
6. Yeast-two hybrid screen 
 
-The yeast two-hybrid screen using full-length murine SAN1 as bait was carried 
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out by Hybrigenics Corporation, Cambridge, MA using a mouse brain library. 
Additional putative interacting proteins shown in Appendix I (Figure 24).  
 
7. Cell cycle analysis 
 
-HeLa cells were transfected with indicated siRNA and then treated with vehicle or 
5 µM Cisplatin for 2 hrs, replaced with fresh media and 24 hrs later harvested for 
flow cytometric analysis. Cells were washed in PBS and then fixed in ice-cold 70% 
ethanol for at least 2 hrs. The cells were washed in PBS and resuspended in 
propidium iodide staining solution (PBS, 0.1% TritonX-100, 0.2 mg/mL DNase-
free RNase A (Sigma), 20 µg/m LPI (Sigma)) and analyzed using a FACSCalibur 
machine (BD). 
 
8. Radial Chromosome Assays 
   
-HeLa cells were incubated for 48 hrs in the presence or absence of MMC. 
Colcemid (0.1 g/ml) was added to the medium 2 hrs before the cells were collected. 
For each sample, 50 metaphases were analyzed for chromosomal abnormalities, as 
previously described (Shimamura et al., 2002). Data were analyzed in Prism 
GraphPad from contingency tables using Fisher’s exact-test (two-sided P value). 
 
9. Proliferation Assay 
 
-HeLa cells and SAN1-/- HeLa cells were plated in 6 well plates at 100 cells/well 
and allowed to adhere. Each day a number of the wells were counted. Relative cell 
growth was determined by dividing each time point by day 1. 
 
10. Electrophoretic Mobility Shift Assay with SAN1 D90A 
 
-32P-labeled X4 (1 nM) was incubated with different concentrations of SAN1 D90A 
(0, 1, 5, 10, 20 nM) or RPA (10 nM) in binding buffer (20 mM HEPES pH 7.4, 
0.1% NP-40, 0.1 M KCl, 5 mM MgCl2, 1% glycerol, 0.25 µg/µl BSA, 1 mM DTT) 
for 30 minutes at room temperature. 4 µl of 6X Ficoll loading dye was added to the 
reactions and 10 µl of each reaction was separated by electrophoresis on a 5% gel 
(37.5:1 polyacrylamide, 0.5X TBE) at 30 V for 3 hrs in a cold room with pre-
chilled 0.5X TBE. Gels were dried and visualized by autoradiography. 
 
11. Double-affinity Strep-FLAG WT and D90A SAN1 purification 
 
-HeLa SAN1-/- cells + SAN1 WT-SSF or SAN1 D90A-SSF cells were washed once 
with 1X PBS followed by addition of Lysis Buffer 1 (50 mM Tris HCl pH 7.4, 1 
mM MgCl2, protease inhibitors (Roche). Samples were snap frozen in liquid 
nitrogen and subsequently thawed at 37°C three times. NaCl was added to 150 mM. 
Lysates were then centrifuged at 16,100 x g for 20 min at 4°C and the supernatant 
was added to washed Strep-Tactin beads (IBA) and rotated for 1 hour at 4°C. 
Samples were washed 2X with Wash Buffer (50 µM Tris HCl pH 7.4, 150 mM 
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NaCl, protease inhibitors) for 15 min rotating per wash at 4°C. SAN1 protein was 
eluted from beads with Elution Buffer (50 mM Tris HCL pH 7.4, 150 mM NaCl, 1 
mM MgCl2, 2.5 mM desthiobiotin) by shaking (600 rpm) at 4°C for 30 min. 
Samples were then added to equal volume of 2X Lysis Buffer 2 (50mM HEPES pH 
7.4, 20% glycerol, 2 mM EDTA, 2mM DTT, 40 nM calyculin A (Sigma) and 
protease inhibitors (Roche)) and added to washed mouse anti-FLAG M2 agarose 
(Sigma) rotating for 1 hr at 4°C. Samples were washed 1X with Wash Buffer (Lysis 
Buffer 2 plus 0.1% NP-40 and 150 mM NaCl) for 15 min  rotating at 4°C. Samples 
were then washed 1X with Elution Buffer (62.5 mM HEPES pH 7.4, 62.5 mM KCl, 
5% glycerol, 1 mM DTT) for 15 min rotating at 4*C. SAN1 protein was eluted 
from beads with Elution Buffer + 150 ng/µL FLAG peptide by shaking (600 rpm) 
at 4°C for 30 min. Samples from each step of the double-affinity Strep-FLAG 
purification were visualized by SDS-PAGE followed by silver stain or immunoblot 
(using mouse M2 anti-FLAG antibody 1:1000, Sigma) or were tested for nuclease 
activity using the nuclease filter-spin assay described previously. 
12. Kinetic Characterization of hSAN1 
 
-Reactions were carried out with varied concentrations of substrate (10 -1000 nM) 
and 240 pmol enzyme in Elution Buffer. Reactions containing SAN1 WT and 
substrate were pre-warmed to 37 °C and initiated by the addition of Start Buffer. 
Reactions were sampled at 3 time points by addition of Stop buffer, and processed 
using the Nucleotide Removal kit (Qiagen). Products were quantified using 
Ecoscint Original scintillation liquid (National Diagnostics) and a scintillation 
counter and were analyzed using GraphPad Prism. 
 
13. Co-IP of N-terminus and C-terminus of SAN1 
 
-15 µg of pKhSAN1-Nuclease-FLAG and 15 µg of pKMyc-mSAN1-Cterminus 
were co-transfected into 293T cells by calcium phosphate transfection. In samples 
where only pKhSAN1-Nuclease-FLAG or pKMyc-mSAN1-Cterminus was 
transfected, 30 µg of DNA was used. Cells were lysed in buffer containing 25 mM 
HEPES pH 7.4, 150 mM NaCl, 0.5% Triton-X 100, 0.5 mM EDTA, 1 mM MgCl2, 
2 mM DTT, 1 mM PMSF, 10 µg/ml leupeptin, 20 ug/ml aprotinin 24 hrs later. Cell 
lysates were then incubated with anti-FLAG M2 agarose for 1 hr at 4°C rotating 
before 3 washes. Samples were boiled for 8 min in 4X LSB and analyzed by 
immunoblot (Myc 1:1000 9E10 clone, FLAG 1:1000 Sigma F1804). pKMycRhoA 
was co-expressed with pKhSAN1-Nuclease-FLAG as a negative control. 
 
14. Recombinant murine SAN1 expression and purification 
 
-The pASK-SAN1 plasmids were transformed into BL21-CodonPlus (DE3)-RIPL 
bacterial cells. SAN1 expression was induced by the addition of tetracycline (0.2 
µg/mL) to 0.5 L of bacteria in early exponential phase in liquid culture followed by 
overnight incubation at 18°C with shaking at 250 rpm. Cells were centrifuged 
(5000 rpm, 20 min, 4°C) and the pellet was resuspended in lysis buffer (50 mM 
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Tris HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 mM PMSF, protease inhibitors 
(Roche)). Lysates were treated with lysozyme (1mM, 4°C, 15 min) before being 
ruptured in a French Press (1500 psi) twice. Lysates were then centrifuged (13.2 
rpm, 20 min, 4°C). The supernatant was loaded onto a pre-equilibrated 1 mL CV 
Gravity flow Strep-Tactin Sepharose column (IBA). The column was washed with 
20 CV buffer w (50 mM Tris HCl pH 7.4, 150 mM NaCl) and eluted with buffer e 
(50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM MgCl2, 2.5 mM desthiobiotin) in 
2.5 mL fractions. Samples from each elution fraction were subjected to SDS-
PAGE.  Fractions containing SAN1 were combined and protein concentration was 
estimated by SDS-PAGE followed by brilliant blue staining in parallel with known 
amounts of BSA.  
 
15. Colony Survival Assays 
 
-HeLa or mouse embryonic fibroblast cells were seeded at 300-400 cells per 6 well 
dish for 16 hrs overnight, treated with DNA damaging agents, and allowed to form 
colonies for 7-10 days. Colonies were fixed in ice cold 70% EtOH, stained with 
crystal violet, and counted. 
 
16. Cell Culture and Transfections 
 
-HeLa (ATCC) and 293T (ATCC) cells were grown in DMEM supplemented with 
10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin (GIBCO). 
Transfection of plasmids or siRNA was performed with calcium phosphate, 
Lipofectamine 2000 (Invitrogen), or Lipofectamine RNAiMAX (Invitrogen). Virus 
was made, collected and titered as described previously (McCaffrey et al. 2009). 
Cell lines verified mycoplasm free by DAPI staining. Cell lines validated by DNA 
sequencing. 
 
17. Production of SAN1-/- HeLa cells 
 
-Two 60-bp guide sequences (sgRNA1 F: 5′-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGCAGGATAA
GAGAGATGAAT -3′ and sgRNA2 F: 5’ – 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAGAAGCTC
TGTGAGAGTCT – 3’) were designed to target sites in the first exon of SAN1, to 
remove the majority of the nuclease domain. The sgRNA1 and sgRNA2 were 
cloned into gRNA cloning vectors and verified by sequencing. gRNA1, gRNA2, 
and NLS-hCas9-NLS constructs were transfected into HeLa cells using 
Lipofectamine 2000 (Invitrogen 11668-030) per Invitrogen protocol publication 
number MAN0007824 Rev 1.0 and seeded at single cell density on 15 cm dishes. 
Individual colonies were isolated by 0.25% trypsin and were plated separately in 6 
well plates to grow. Genomic DNA was isolated from WT HeLa cells and from 12 
clones. Exon 1 of SAN1 was PCR amplified using SAN1 genomic PCR primers 
(SAN1 genomic F: 5’ – ACTGATTAATTTATCTTTCTTTCCAGATCC – 3’ and 
SAN1 genomic R: 5’TCTGGGATTATGTCGTTGCCAAGGAGG – 3’) and clones 
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that showed a deletion were sequenced and analyzed by immunoblot (SAN1 
1:1000). 6 SAN1-/- HeLa clones were identified and experiments in this study were 
completed with SAN1-/- HeLa Clone 2 unless otherwise specified.  
 
18. Generation of Mouse Embryonic Fibroblasts (MEFs)  
 
-A conditional KO mouse was created through the Texas A&M Institute for 
Genomic Medicine, using EUCOMM ES cells targeting the fam120b gene (ES cell 
clone HEPD0652_5_G10). A fam120b/+ male was crossed to a FLPer/+ female to 
delete the lacz/neo markers, the FLPer transgene was then removed by crossing to a 
+/+ mouse, and the resulting floxed allele mice were crossed to produce 
homozygotes. These were then crossed with a Sox2-Cre mouse to obtain a global 
knockout of the allele. Fam120b +/+ and -/- MEFs were isolated from day 13.5 
embryos, from matings of heterozygous parents. Embryos were incubated in 0.25% 
Trypsin overnight at 4° C for digestion to single cells. Cells were plated and 
cultured in 10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin (GIBCO). 
MEFs were immortalized by transfection with a plasmid encoding SV40 Large T 
antigen (Addgene 21826), followed by a 1/10 split of the cells 5-6 times. 
Genotypes were validated by genomic PCR and western blotting using a non-
commercial rabbit polyclonal antibody against murine SAN1 (1:1000).
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